

Fourth Joint Task Force of the European Society of Cardiology and the
International Society of Hypertension (Task Force on Cardiovascular Disease Prevention in Clinical Practice)

European Journal of Cardiovascular Prevention and Rehabilitation
14, S1-S1

DOI: 10.1097/01.hjr.0000277983.23934.c9

Citation Report

#	ARTICLE	IF	CITATIONS
2	High time to join hands between family medicine and cardiology!. European Heart Journal, 2007, 28, 2962-2963.	1.0	2
3	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1 1 0:78431478BT/Ov	1.0	2,331
4	The burden of hyperlipidaemia and diabetes in cardiovascular diseases. Fundamental and Clinical Pharmacology, 2007, 21, 1-3.	1.0	30
5	Diagnostik der koronaren Herzkrankheit mittels kardialer Computertomographie. Clinical Research in Cardiology Supplements, 2007, 2, V37-V48.	2.0	1
6	Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. International Journal of Cardiovascular Imaging, 2008, 24, 645-671.	0.7	94
7	Atherosclerotic Cardiovascular Diseases in Belgium: A Cost-of-illness Analysis. Cardiovascular Drugs and Therapy, 2008, 22, 487-494.	1.3	10
8	Cardiovascular risk factors and mortality in patients with coronary heart disease. European Journal of Epidemiology, 2008, 23, 731-737.	2.5	28
10	Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. Journal of Cancer Survivorship, 2008, 2, 128-137.	1.5	40
11	Analyse des kardiovaskulären Risikos mittels Kardio-CT und Koronarkalkbestimmung. Clinical Research in Cardiology Supplements, 2008, 3, 48-57.	2.0	0
13	Primary prevention of diabetes mellitus type 2 and cardiovascular diseases using a cognitive behavior program aimed at lifestyle changes in people at risk: Design of a randomized controlled trial. BMC Endocrine Disorders, 2008, 8, 6.	0.9	40
14	Vitalum study design: RCT evaluating the efficacy of tailored print communication and telephone motivational interviewing on multiple health behaviors. BMC Public Health, 2008, 8, 216.	1.2	37
15	Implementing the European guidelines for cardiovascular disease prevention in the primary care setting in Cyprus: Lessons learned from a health care services study. BMC Health Services Research, 2008, 8, 148.	0.9	12
16	Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins. Clinical Drug Investigation, 2008, 28, 625-634.	1.1	34
19	Cardiovascular Risk Factors. Insights From Framingham Heart Study. Revista Espanola De Cardiologia (English Ed), 2008, 61, 299-310.	0.4	112
20	Global Preventive Policies. Strategies at European and Worldwide Level. Revista Espanola De Cardiologia (English Ed), 2008, 61, 960-970.	0.4	1
21	Re-Evaluating Therapeutic Target Goals for Statin-Treated Patients. Journal of the American College of Cardiology, 2008, 52, 633-635.	1.2	4
22	Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events. Journal of Clinical Lipidology, 2008, 2, 343-353.	0.6	7
23	Assessment of lipid-lowering treatment in France – The CEPHEUS study. Archives of Cardiovascular Diseases, 2008, 101, 557-563.	0.7	28

#	ARTICLE	IF	CITATIONS
24	A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE). Archives of Cardiovascular Diseases, 2008, 101, 723-735.	0.7	6
25	Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opinion on Pharmacotherapy, 2008, 9, 2145-2160.	0.9	36
26	Pharmacist-Led Interventions for the Management of Cardiovascular Disease. Disease Management and Health Outcomes, 2008, 16, 131-144.	0.3	6
27	Statins in heart failure – A failure?. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 397-401.	1.1	1
28	Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: Results from two open-label extension studies in hypercholesterolemic patients. Clinical Therapeutics, 2008, 30, 2280-2297.	1.1	7
29	Laboratory-based versus non-laboratory-based CVD risk analysis. Lancet, The, 2008, 371, 2081.	6.3	0
30	The concept of cardiometabolic risk: Bridging the fields of diabetology and cardiology. Annals of Medicine, 2008, 40, 514-523.	1.5	75
31	Cardiovascular Risk Management in Clinical Practice. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 9-16.	1.0	4
32	Global Cardiovascular Disease Risk Management in Italian Patients with Metabolic Syndrome in the Clinical Practice Setting. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 37-45.	1.0	2
33	The Clinical Significance of Metabolic Syndrome in Hypertension: Metabolic Syndrome Increases Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 59-62.	1.0	1
34	2008 White Paper for Implementing Strategies and Interventions for Cardiovascular Prevention in Italy. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 63-73.	1.0	4
35	A New Option for Therapeutic Management of Patients with Cerebrovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 105-107.	1.0	1
36	Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor. Scandinavian Journal of Rheumatology, 2008, 37, 321-328.	0.6	103
37	Colesevelam hydrochloride: a specifically engineered bile acid sequestrant. Future Lipidology, 2008, 3, 237-255.	0.5	15
38	Ankle Brachial Index Combined With Framingham Risk Score to Predict Cardiovascular Events and Mortality. JAMA - Journal of the American Medical Association, 2008, 300, 197.	3.8	1,553
39	Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study. Current Medical Research and Opinion, 2008, 24, 3149-3157.	0.9	7
40	Lipids, statins and cardiovascular disease. Climacteric, 2008, 11, 348-350.	1.1	0
41	Heartwatch: a secondary prevention programme in primary care in Ireland. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 651-656.	3.1	12

#	ARTICLE	IF	CITATIONS
42	The management of the type 2 diabetic patient with hypertension "too late and too little: Suggested improvements. <i>Blood Pressure</i> , 2008, 17, 250-259.	0.7	7
43	Composantes de la capacit�� d'auto-soin de personnes ayant subi un infarctus du myocarde et participant � un programme d'exercices � domicile. <i>Revue De L'Universit�� De Moncton</i> , 0, 39, 249-273.	0.0	0
45	European guidelines on cardiovascular disease prevention in clinical practice: past, present, and future: a need for joint forces. <i>Journal of Hypertension</i> , 2008, 26, 157-160.	0.3	4
47	Cardiovascular risk in women with polycystic ovary syndrome. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 987-992.	0.6	62
49	Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 991-1000.	1.0	53
50	Cardiovascular Risk Assessment of Bulgarian Urban Population: Cross-Sectional Study. <i>Croatian Medical Journal</i> , 2008, 49, 783-791.	0.2	11
52	Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. <i>Vascular Health and Risk Management</i> , 2009, 5, 921.	1.0	43
53	Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. <i>Current Medical Research and Opinion</i> , 2009, 25, 1973-1983.	0.9	37
54	Who does not need a statin: too late in end-stage renal disease or heart failure?. <i>Postgraduate Medical Journal</i> , 2009, 85, 187-189.	0.9	5
55	Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 698-704.	3.1	14
56	Elevated Risk Profile of Women in Secondary Prevention of Coronary Artery Disease: A 6-Year Survey of 117,913 Patients. <i>Journal of Women's Health</i> , 2009, 18, 1123-1131.	1.5	21
57	Perspectives on low-density lipoprotein cholesterol goal achievement. <i>Current Medical Research and Opinion</i> , 2009, 25, 431-447.	0.9	39
58	Risk factor management after acute coronary syndromes. <i>Heart</i> , 2009, 95, 1382-1384.	1.2	5
59	Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 1-9.	3.1	24
60	New European guidelines for cardiovascular disease prevention in clinical practice. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 138-42.	1.4	12
61	A Historical Perspective of the Understanding of the Link Between Diet and Coronary Heart Disease. <i>American Journal of Lifestyle Medicine</i> , 2009, 3, 35S-38S.	0.8	11
62	Non-invasive assessment of vulnerable plaque. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 53-66.	1.6	4
63	Towards companion diagnostics for the management of statin therapy. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 659-671.	1.6	0

#	ARTICLE	IF	CITATIONS
64	Translation of evidence-based guidelines in preventive cardiology: the EUROACTION program. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 8-9.	3.3	1
65	Treatment of combined hypertension and orthostatic hypotension in older adults: more questions than answers still remain. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 557-560.	0.6	12
66	Long-term secondary prevention programs after cardiac rehabilitation for the reduction of future cardiovascular events: focus on regular physical activity. <i>Future Cardiology</i> , 2009, 5, 297-314.	0.5	10
67	Should All Diabetic Patients Be Treated With a Statin?. <i>Diabetes Care</i> , 2009, 32, S378-S383.	4.3	15
68	Increased carotid intima-media thickness in patients with pheochromocytoma in comparison to essential hypertension. <i>Journal of Human Hypertension</i> , 2009, 23, 350-358.	1.0	15
69	Evaluating the causal relevance of diverse risk markers: horizontal systematic review. <i>BMJ: British Medical Journal</i> , 2009, 339, b4265-b4265.	2.4	40
70	Novel Pathogenic Insights in the Primary Prevention of Cardiovascular Disease. <i>Progress in Cardiovascular Diseases</i> , 2009, 51, 503-523.	1.6	23
71	Physical distress is associated with cardiovascular events in a high risk population of elderly men. <i>BMC Cardiovascular Disorders</i> , 2009, 9, 14.	0.7	14
72	How to Identify the Asymptomatic High-Risk Patient?. <i>Current Problems in Cardiology</i> , 2009, 34, 539-577.	1.1	3
73	Usefulness of Statin+Ezetimibe Combination to Reduce the Care Gap in Dyslipidemia Management in Patients With a High Risk of Atherosclerotic Disease. <i>American Journal of Cardiology</i> , 2009, 104, 798-804.e2.	0.7	15
74	Comparison of the Value of Coronary Calcium Detection to Computed Tomographic Angiography and Exercise Testing in Patients With Chest Pain. <i>American Journal of Cardiology</i> , 2009, 104, 1499-1504.	0.7	44
77	Effects of selective If-channel inhibition with ivabradine on hemodynamics in a patient with restrictive cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2009, 98, 681-684.	1.5	6
78	Beyond Type D personality: reduced positive affect (anhedonia) predicts impaired health status in chronic heart failure. <i>Quality of Life Research</i> , 2009, 18, 689-98.	1.5	36
79	Brief Depression Screening with the PHQ-2 Associated with Prognosis Following Percutaneous Coronary Intervention with Paclitaxel-Eluting Stenting. <i>Journal of General Internal Medicine</i> , 2009, 24, 1037-1042.	1.3	28
80	Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. <i>Advances in Therapy</i> , 2009, 26, 469-487.	1.3	13
81	Dyslipidemia therapy update: the importance of full lipid profile assessment. <i>Advances in Therapy</i> , 2009, 26, 711-718.	1.3	10
82	Long-Term Effects of a Multimodal Behavioral Intervention on Myocardial Perfusion—a Randomized Controlled Trial. <i>International Journal of Behavioral Medicine</i> , 2009, 16, 219-226.	0.8	19
85	Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. <i>Diabetologia</i> , 2009, 52, 415-424.	2.9	142

#	ARTICLE	IF	CITATIONS
86	Cardiovascular Prevention in Clinical Practice (ESC and German Guidelines 2007). Herz, 2009, 34, 4-14.	0.4	12
87	The role of incretin-based therapies in the management of type 2 diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2009, 26, 186.	0.2	1
88	Smoking among diabetes patients in Yogyakarta, Indonesia: cessation efforts are urgently needed. Tropical Medicine and International Health, 2009, 14, 412-419.	1.0	19
89	Obesity and trends in cardiovascular risk factors over 40 years in Swedish men aged 50. Journal of Internal Medicine, 2009, 266, 268-276.	2.7	33
90	Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. British Journal of Clinical Pharmacology, 2009, 67, 355-362.	1.1	26
91	Non-invasive measurement of the haemodynamic effects of inhaled salbutamol, intravenous L-arginine and sublingual nitroglycerin. British Journal of Clinical Pharmacology, 2009, 68, 23-33.	1.1	13
92	SEARCHing for JUPITER: starry-eyed optimism is not warranted. International Journal of Clinical Practice, 2009, 63, 685-688.	0.8	5
93	Vascular risk screening: possible or too much, too soon?. International Journal of Clinical Practice, 2009, 63, 989-996.	0.8	6
94	Inclusion of Dietary Evaluation in Cardiovascular Disease Risk Prediction Models Increases Accuracy and Reduces Bias of the Estimations. Risk Analysis, 2009, 29, 176-186.	1.5	11
95	Risk factors associated with the presence of diabetes in Chinese communities in Beijing. Diabetes Research and Clinical Practice, 2009, 86, 233-238.	1.1	13
96	How to improve cardiovascular diseases prevention in Europe?. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 451-454.	1.1	28
97	Effects of a global health and risk assessment tool for prevention of ischemic heart disease in an individual health dialogue compared with a community health strategy only. Preventive Medicine, 2009, 48, 20-24.	1.6	13
101	Additional prognostic value of physical examination, exercise testing, and arterial ultrasonography for coronary risk assessment in primary prevention. American Heart Journal, 2009, 158, 845-851.	1.2	31
103	Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007. Archives of Cardiovascular Diseases, 2009, 102, 293-301.	0.7	64
104	The impact of glucose-lowering therapy on cardiovascular outcomes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 401-411.	2.2	14
106	Analysis of cardiovascular responses to passive head-up tilt using continuous pulse wave analysis and impedance cardiography. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 128-137.	0.6	67
107	Treatment of Patients With Coronary Heart Disease Fails to Meet Standards of European Guidelines: Results of EUROASPIRE Surveys. Revista Espanola De Cardiologia (English Ed), 2009, 62, 1095-1098.	0.4	5
109	Omega-3 Ethylester Concentrate. Drugs, 2009, 69, 1077-1105.	4.9	41

#	ARTICLE	IF	CITATIONS
110	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Blood Pressure</i> , 2009, 18, 308-347.	0.7	351
111	Cardiac rehabilitation in Austria: long term health-related quality of life outcomes. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 99.	1.0	22
112	Healthy lifestyle interventions in general practice Part 8: Lifestyle and dyslipidaemia. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2009, 51, 453-460.	0.2	1
114	Physicians' attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: cross-sectional survey in three world regions. <i>Current Medical Research and Opinion</i> , 2009, 25, 1171-1178.	0.9	67
115	Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. <i>Blood Pressure</i> , 2009, 18, 111-116.	0.7	8
116	Advances in cardiac imaging: the role of magnetic resonance imaging and computed tomography in identifying athletes at risk. <i>British Journal of Sports Medicine</i> , 2009, 43, 677-684.	3.1	27
118	Arterial stiffness and wave reflection: Biomarkers of cardiovascular risk. <i>Artery Research</i> , 2009, 3, 56.	0.3	167
120	Bridging science and health policy in cardiovascular disease: focus on lipid management. <i>Atherosclerosis Supplements</i> , 2009, 10, 3-21.	1.2	10
121	The Lorenzini Foundation in a changing scenario of patient management. <i>Atherosclerosis Supplements</i> , 2009, 10, 22-28.	1.2	0
122	International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 472-480.	3.1	13
123	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. <i>Canadian Journal of Cardiology</i> , 2009, 25, 567-579.	0.8	653
124	Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. <i>Lancet, The</i> , 2009, 373, 929-940.	6.3	737
125	Secondary cardiovascular risk prevention – we can do better. <i>Lancet, The</i> , 2009, 373, 873-875.	6.3	8
129	Triglicéridos en ayunas y posprandiales, y su contribución al estudio del riesgo cardiometabólico. <i>Clínica e Investigación En Arteriosclerosis</i> , 2009, 21, 290-297.	0.4	0
131	Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. <i>Journal of Hypertension</i> , 2009, 27, 941-946.	0.3	29
132	2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. <i>Journal of Hypertension</i> , 2009, 27, S3-S11.	0.3	31
133	Noninvasive methods for assessing early markers of atherosclerosis: the role of body composition and nutrition. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2009, 12, 467-473.	1.3	14
134	Postmenopausal hormone therapy and the risk of cardiovascular disease. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 303-309.	0.6	11

#	ARTICLE	IF	CITATIONS
135	Central blood pressure and hypertension: role in cardiovascular risk assessment. <i>Clinical Science</i> , 2009, 116, 273-282.	1.8	60
136	Future Challenges for Microsomal Transport Protein Inhibitors. <i>Current Vascular Pharmacology</i> , 2009, 7, 277-286.	0.8	43
137	Global Cardiovascular Risk Assessment in Different Clinical Settings. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2009, 16, 55-63.	1.0	13
138	The potential yield of ECG screening of hypertensive patients: the Utrecht Health Project. <i>Journal of Hypertension</i> , 2010, 28, 1527-1533.	0.3	18
139	Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD. <i>Current Cardiology Reviews</i> , 2010, 6, 112-118.	0.6	21
140	Blood pressure up in a puff of smoke. <i>Journal of Hypertension</i> , 2010, 28, 1806-1808.	0.3	2
141	Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. <i>Current Opinion in Lipidology</i> , 2010, 21, 492-498.	1.2	95
142	Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 825-834.	1.2	2
143	Asymptomatic carotid lesions add to cardiovascular risk prediction. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 514-518.	3.1	20
144	Barriers to Routine Risk-Score Use for Healthy Primary Care Patients. <i>Archives of Internal Medicine</i> , 2010, 170, 719.	4.3	64
145	Home-based versus centre-based cardiac rehabilitation. , 2010, , CD007130.		330
148	Cardiological evaluation after cerebral ischaemia. <i>Clinical Research in Cardiology</i> , 2010, 99, 609-625.	1.5	16
150	Extracellular heat shock protein 70 (HSPA1A) and classical vascular risk factors in a general population. <i>Cell Stress and Chaperones</i> , 2010, 15, 929-937.	1.2	49
151	Assessment of Cardiovascular Risk. <i>Current Hypertension Reports</i> , 2010, 12, 384-393.	1.5	13
152	Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. , 2010, 126, 314-345.		196
153	Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). <i>BMC Public Health</i> , 2010, 10, 382.	1.2	22
154	EDUCORE project: a clinical trial, randomised by clusters, to assess the effect of a visual learning method on blood pressure control in the primary healthcare setting. <i>BMC Public Health</i> , 2010, 10, 449.	1.2	4
155	Type D personality is associated with increased metabolic syndrome prevalence and an unhealthy lifestyle in a cross-sectional Dutch community sample. <i>BMC Public Health</i> , 2010, 10, 714.	1.2	80

#	ARTICLE	IF	CITATIONS
156	Rationale and methods of the cardiometabolic valencian study (escarval-risk) for validation of risk scales in mediterranean patients with hypertension, diabetes or dyslipidemia. BMC Public Health, 2010, 10, 717.	1.2	19
157	Bio-psychosocial determinants of cardiovascular disease in a rural population on Crete, Greece: formulating a hypothesis and designing the SPILI-III study. BMC Research Notes, 2010, 3, 258.	0.6	7
158	Safety and Efficacy of Ezetimibe Added to Atorvastatin Versus Up Titration of Atorvastatin to 40 mg in Patients ≥65 Years of Age (from the ZETia in the ELDERly [ZETELED] Study). American Journal of Cardiology, 2010, 105, 656-663.	0.7	45
159	Comparison of Usefulness of Exercise Testing Versus Coronary Computed Tomographic Angiography for Evaluation of Patients Suspected of Having Coronary Artery Disease. American Journal of Cardiology, 2010, 105, 773-779.	0.7	22
160	Safety and Efficacy of Ezetimibe/Simvastatin Combination Versus Atorvastatin Alone in Adults ≥65 Years of Age With Hypercholesterolemia and With or at Moderately High/High Risk for Coronary Heart Disease (the VYTELD Study). American Journal of Cardiology, 2010, 106, 1255-1263.	0.7	22
163	Risk scores and decision making: the anatomy of a decision to reduce breast cancer risk. Journal of Nursing and Healthcare of Chronic Illness, 2010, 2, 271-280.	0.5	11
164	Myocardial perfusion scintigraphy in asymptomatic diabetic patients: a critical review. Diabetes/Metabolism Research and Reviews, 2010, 26, 336-347.	1.7	15
166	Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovascular Diabetology, 2010, 9, 20.	2.7	24
167	Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study. Value in Health, 2010, 13, 726-734.	0.1	20
168	Combined therapy in the treatment of dyslipidemia. Fundamental and Clinical Pharmacology, 2010, 24, 19-28.	1.0	81
169	Gender-specific aspects in the clinical presentation of cardiovascular disease. Fundamental and Clinical Pharmacology, 2010, 24, 711-717.	1.0	30
170	Role of adipokines in obesity-associated hypertension. Acta Physiologica, 2010, 200, 107-127.	1.8	41
171	Application of cardioprotective medication. International Journal of Clinical Practice, 2010, 64, 529-532.	0.8	0
172	Attainment of Canadian and European guidelines™ lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. International Journal of Clinical Practice, 2010, 64, 1765-1772.	0.8	4
173	Clinical significance of low-grade renal artery stenosis. Journal of Internal Medicine, 2010, 267, 305-315.	2.7	17
174	Obesity, smoking and secular trends in cardiovascular risk factors in middle-aged women: data from population studies in GÅrteborg from 1980 to 2003. Journal of Internal Medicine, 2010, 268, 594-603.	2.7	22
175	Psychological well-being in obese inpatients with ischemic heart disease at entry and at discharge from a four-week cardiac rehabilitation program. Frontiers in Psychology, 2010, 1, 38.	1.1	16
176	Perceptions of risk: understanding cardiovascular disease. Risk Management and Healthcare Policy, 2010, 3, 49.	1.2	91

#	ARTICLE	IF	CITATIONS
177	Original research Risk factor control and adherence to treatment in patients with coronary heart disease in the Republic of Srpska, Bosnia and Herzegovina in 2005-2006. Archives of Medical Science, 2010, 2, 183-187.	0.4	12
178	Management of overweight and obese patients with coronary heart disease across Europe. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 447-454.	3.1	36
179	Systematic Review of Guidelines on Cardiovascular Risk Assessment. Archives of Internal Medicine, 2010, 170, 27.	4.3	116
180	Cardiovascular Risk Factors and Estimated 10-Year Risk of Fatal Cardiovascular Events Using Various Equations in Greeks With Metabolic Syndrome. Angiology, 2010, 61, 49-57.	0.8	14
181	Arterial Stiffness and Cardiovascular Events. Circulation, 2010, 121, 505-511.	1.6	1,824
182	Which lipid fraction is the target and how often should this be monitored?. Heart, 2010, 96, 413-414.	1.2	4
183	Mehran Contrast-Induced Nephropathy Risk Score Predicts Short- and Long-Term Clinical Outcomes in Patients With ST-Elevationâ€œMyocardial Infarction. Circulation: Cardiovascular Interventions, 2010, 3, 491-498.	1.4	114
185	Lipid lowering goals: back to nature?. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 185-191.	1.0	13
186	Antihypertensive and organ-protective effects of benazepril. Expert Review of Cardiovascular Therapy, 2010, 8, 1653-1671.	0.6	6
187	Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RiSk (AMORIS) Study. Annals of the Rheumatic Diseases, 2010, 69, 1996-2001.	0.5	121
188	Predictors of Successful Smoking Cessation in a Family Practice-Based Cardiovascular Risk Factor Intervention Program: â€œReal-Worldâ€™ Experience From the Heartwatch Program. Journal of Smoking Cessation, 2010, 5, 151-157.	0.3	0
189	Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clinical Lipidology, 2010, 5, 655-684.	0.4	33
190	Why Patients Should Be More Empowered: A European Perspective on Lessons Learned in the Management of Diabetes. Journal of Diabetes Science and Technology, 2010, 4, 1570-1573.	1.3	40
191	Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. BMJ: British Medical Journal, 2010, 340, b5631-b5631.	2.4	354
192	Food and vessels: the importance of a healthy diet to prevent cardiovascular disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 50-55.	3.1	43
193	Quality Indicators for the Prevention of Type 2 Diabetes in Europe â€œ IMAGE. Hormone and Metabolic Research, 2010, 42, S56-S63.	0.7	40
194	The Effects of Isolated versus Multiple Lipid Disorders on Resource Utilization among Metabolic Syndrome Patients with Lipid Abnormalities despite Lipid-Modifying Treatment. Cardiology, 2010, 117, 96-104.	0.6	2
195	Optimizing lipid-lowering therapy in the prevention of coronary heart disease. Expert Review of Clinical Pharmacology, 2010, 3, 649-661.	1.3	0

#	ARTICLE	IF	CITATIONS
196	Evaluation of strategies of care in the secondary prevention of heart disease: critical appraisal of a cluster randomized trial. <i>Future Cardiology</i> , 2010, 6, 459-462.	0.5	1
197	Raising HDL cholesterol levels: a flight of Icarus?. <i>Nature Reviews Endocrinology</i> , 2010, 6, 245-246.	4.3	0
198	Vascular preventive measures: the progression from asymptomatic to symptomatic atherosclerosis management. Evidence on usefulness of early diagnosis in women and children. <i>Future Cardiology</i> , 2010, 6, 211-220.	0.5	4
199	Physicians'™ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: The PERCRO-DOC survey. <i>Atherosclerosis</i> , 2010, 213, 598-603.	0.4	118
200	A "Hot" Topic in Dyslipidemia Management" – How to Beat a Flush: Optimizing Niacin Tolerability to Promote Long-term Treatment Adherence and Coronary Disease Prevention. <i>Mayo Clinic Proceedings</i> , 2010, 85, 365-379.	1.4	37
201	Uso de antiaqreantes en la diabetes. <i>Avances En DiabetologÃa</i> , 2010, 26, 24-28.	0.1	1
203	Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High Risk Hypercholesterolemic Patients Stratified by Previous Statin Treatment Potency. <i>Journal of Clinical Lipidology</i> , 2010, 4, 207-208.	0.6	0
204	Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients. <i>Journal of Clinical Lipidology</i> , 2010, 4, 272-278.	0.6	10
205	Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: Results of the CENTAURUS study. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 160-169.	0.7	24
206	Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 302-309.	0.7	13
207	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting. <i>Thrombosis and Haemostasis</i> , 2010, 103, 13-28.	1.8	292
208	Drug-eluting stents in patients on long-term oral anticoagulation therapy: a mission impossible?. <i>Interventional Cardiology</i> , 2010, 2, 127-135.	0.0	4
209	CT coronary angiography and exercise ECG in a population with chest pain and low-to-intermediate pre-test likelihood of coronary artery disease. <i>Heart</i> , 2010, 96, 1973-1979.	1.2	33
210	Niacin in the prevention of atherosclerosis: Significance of vasodilatation. <i>Medical Hypotheses</i> , 2010, 75, 397-400.	0.8	4
211	Predictive ability of the SCORE Belgium risk chart for cardiovascular mortality. <i>International Journal of Cardiology</i> , 2010, 143, 385-390.	0.8	32
212	The influence of long-term awareness of hyperlipidemia and of 3 years of dietary counseling on depression, anxiety, and quality of life. <i>Journal of Psychosomatic Research</i> , 2010, 68, 567-572.	1.2	21
215	Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome. <i>Growth Hormone and IGF Research</i> , 2010, 20, 179-184.	0.5	60
216	The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. <i>European Journal of Internal Medicine</i> , 2010, 21, 293-296.	1.0	11

#	ARTICLE	IF	CITATIONS
217	Randomised controlled trial of additional lifestyle support for the reduction of cardiovascular disease risk through primary care in Stoke-on-Trent, UK. <i>Contemporary Clinical Trials</i> , 2010, 31, 345-354.	0.8	8
218	APOE Gene ϵ Polymorphism Does Not Determine Predisposition to Ischemic Stroke in Children. <i>Pediatric Neurology</i> , 2010, 43, 25-28.	1.0	14
219	High cardiovascular risk in Spanish workers. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 21, 231-6.	1.1	25
220	Coronary artery disease: Clinical presentation, diagnosis and prognosis in women. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 426-435.	1.1	17
221	Public perceptions of cardiovascular risk factors in Croatia: The PERCRO survey. <i>Preventive Medicine</i> , 2010, 51, 494-496.	1.6	58
222	Introduction. <i>Atherosclerosis Supplements</i> , 2010, 11, 1-2.	1.2	7
223	Pitavastatin " from clinical trials to clinical practice. <i>Atherosclerosis Supplements</i> , 2010, 11, 15-22.	1.2	19
224	Association between dyslipidemia and vascular events in patients treated with statins: Report from the UK General Practice Research Database. <i>Atherosclerosis</i> , 2010, 208, 210-216.	0.4	17
225	Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. <i>Atherosclerosis</i> , 2010, 211, 676-681.	0.4	134
226	Pitavastatin " results from phase III & IV. <i>Atherosclerosis Supplements</i> , 2010, 11, 8-14.	1.2	16
227	Promoting patient uptake and adherence in cardiac rehabilitation. , 2010, , CD007131.		138
228	Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. <i>Lipids in Health and Disease</i> , 2010, 9, 127.	1.2	6
229	Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. <i>Lipids in Health and Disease</i> , 2010, 9, 80.	1.2	11
230	Combination therapy with prescription omega-3-acid ethyl esters and statin improves non-HDL-C more effectively than statin alone. <i>Clinical Lipidology</i> , 2010, 5, 325-328.	0.4	2
231	Psychological and social factors in coronary heart disease. <i>Annals of Medicine</i> , 2010, 42, 487-494.	1.5	126
232	Serum total cholesterol levels and all-cause mortality in a home-dwelling elderly population: a six-year follow-up. <i>Scandinavian Journal of Primary Health Care</i> , 2010, 28, 121-127.	0.6	51
233	Cardiovascular risk factors are not treated to target in hypertensive patients in primary care. <i>Blood Pressure</i> , 2010, 19, 176-181.	0.7	9
234	Prevalence of "Borderline"™ Values of Cardiovascular Risk Factors in the Clinical Practice of General Medicine in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011, 18, 43-51.	1.0	3

#	ARTICLE	IF	CITATIONS
235	Risk Assessment Tools for Identifying Individuals at Risk of Developing Type 2 Diabetes. <i>Epidemiologic Reviews</i> , 2011, 33, 46-62.	1.3	236
236	Diagnostic and prognostic value of Doppler echocardiographic coronary flow reserve in the left anterior descending artery. <i>Heart</i> , 2011, 97, 1758-1765.	1.2	60
238	Determinación del riesgo cardiovascular total. Caracterización, modelización y objetivos de la prevención según el contexto sociogeográfico. <i>Revista Española De Cardiología Suplementos</i> , 2011, 11, 2-12.	0.2	1
240	On-Clopidogrel Platelet Reactivity. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1955-1957.	1.2	0
241	Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). <i>Journal of Clinical Lipidology</i> , 2011, 5, 474-482.	0.6	22
242	Clinical Nutrition University. The place of nutrition in the prevention of cardiovascular diseases (CVDs). <i>European E-journal of Clinical Nutrition and Metabolism</i> , 2011, 6, e272-e282.	0.4	6
243	Guía de actuación para el farmacéutico comunitario en pacientes con hipertensión arterial y riesgo		

#	ARTICLE	IF	CITATIONS
257	Resistance Training Dose Response in Combined Endurance-Resistance Training in Patients With Cardiovascular Disease: A Randomized Trial. Archives of Physical Medicine and Rehabilitation, 2011, 92, 1527-1533.	0.5	25
258	Challenges and Opportunities for Cardiovascular Disease Prevention. American Journal of Medicine, 2011, 124, 95-102.	0.6	99
259	Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease. American Journal of Medicine, 2011, 124, 621-629.	0.6	134
260	Apolipoprotein A-I, apolipoprotein B, and apolipoprotein B/apolipoprotein A-I ratio: Reference intervals compared with values in different pathophysiological conditions from the FINRISK 2007 study. Clinica Chimica Acta, 2011, 412, 1146-1150.	0.5	10
261	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology, 2011, 27, S1-S59.	0.8	106
262	Environmental and occupational exposure to lead as a potential risk factor for cardiovascular disease. Environmental Toxicology and Pharmacology, 2011, 31, 267-277.	2.0	68
263	Exercise: Should it matter to internal medicine?. European Journal of Internal Medicine, 2011, 22, 363-370.	1.0	12
264	Coronary dual source multi detector computed tomography in patients suspected of coronary artery disease: Prevalence of incidental extra-cardiac findings. European Journal of Radiology, 2011, 80, 109-114.	1.2	25
266	Epistaxis and its complex origin. Medical Hypotheses, 2011, 77, 156-157.	0.8	0
267	Assessment of nurses' nutritional knowledge regarding therapeutic diet regimens. Nurse Education Today, 2011, 31, 192-197.	1.4	20
268	Rationale and design for a cardiovascular screening and prevention study with tele-cardiology in Mediterranean Italy: The CAPITAL study (CARDiovascular Prevention with Telecardiology in Apulia). International Journal of Cardiology, 2011, 149, 130-133.	0.8	12
269	Factors influencing the time-point of acute myocardial infarction in winter tourists. International Journal of Cardiology, 2011, 149, 136-137.	0.8	2
270	A Stepwise Psychotherapy Intervention for Reducing Risk in Coronary Artery Disease (SPIRR-CAD) â€” Rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research, 2011, 71, 215-222.	1.2	50
271	No association between anxiety and depression and adverse clinical outcome among patients with cardiovascular disease: Findings from the DANREHAB trial. Journal of Psychosomatic Research, 2011, 71, 207-214.	1.2	13
272	Type D personality and metabolic syndrome in a 7-year prospective occupational cohort. Journal of Psychosomatic Research, 2011, 71, 357-363.	1.2	24
278	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	1.0	2,767
279	Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand. International Journal of Pharmacy Practice, 2011, 19, 129-135.	0.3	8
280	Doctor contraceptive-prescribing behaviour and women's attitudes towards contraception: two European surveys. Journal of Evaluation in Clinical Practice, 2011, 17, 493-502.	0.9	10

#	ARTICLE	IF	CITATIONS
281	Introduction. <i>Atherosclerosis Supplements</i> , 2011, 12, 265-266.	1.2	8
282	HDL-C: Role as a risk modifier. <i>Atherosclerosis Supplements</i> , 2011, 12, 267-270.	1.2	87
283	Pitavastatin: Novel effects on lipid parameters. <i>Atherosclerosis Supplements</i> , 2011, 12, 277-284.	1.2	17
284	Clinical Applicability of the Framingham 30-Year Risk Score. Usefulness in Cardiovascular Risk Stratification and the Diagnosis of Carotid Atherosclerotic Plaque. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 305-311.	0.4	8
285	Stagnant Cardiovascular Prevention: Professional Barriers. <i>Revista Espanola De Cardiologia (English)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.4	0
286	Comments on the 2011 ESC/EAS guidelines for the management of dyslipidemias. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 1090-1095.	0.4	17
287	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 1-44.	0.4	180
288	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 3-46.	0.4	561
289	Qualitative score of systemic arteriosclerosis by vascular ultrasonography as a predictor of coronary artery disease in type 2 diabetes. <i>Atherosclerosis</i> , 2011, 219, 623-629.	0.4	17
290	Considerable uncertainty remains in the evidence for primary prevention of cardiovascular disease. , 2011, , ED000017.		7
291	The Global Risk Approach Should Be Better Applied in French Hypertensive Patients: A Comparison between Simulation and Observation Studies. <i>PLoS ONE</i> , 2011, 6, e17508.	1.1	20
292	Early Phase 2 Inpatient Rehabilitation after Acute Coronary Syndrome Treated with Primary Percutaneous Coronary Intervention. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2011, 90, 589-598.	0.7	6
293	Total cardiovascular disease risk assessment. <i>Current Opinion in Cardiology</i> , 2011, 26, 429-437.	0.8	8
294	Blood pressure control and knowledge of target blood pressure in coronary patients across Europe. <i>Journal of Hypertension</i> , 2011, 29, 1641-1648.	0.3	89
295	Patient Education and Quality of Home-Based Rehabilitation in Patients Older Than 60 Years After Acute Myocardial Infarction. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2011, 31, 249-253.	1.2	17
296	High blood pressure and obesity. <i>Journal of Hypertension</i> , 2011, 29, 1494-1501.	0.3	12
297	Efficacy of Out-Patient Cardiac Rehabilitation in Low Prognostic Risk Patients After Acute Myocardial Infarction in Primary Intervention Era. <i>Circulation Journal</i> , 2011, 75, 315-321.	0.7	25
298	Non-Invasive Diagnostic Workup of Patients With Suspected Stable Angina by Combined Computed Tomography Coronary Angiography and Magnetic Resonance Perfusion Imaging. <i>Circulation Journal</i> , 2011, 75, 1678-1684.	0.7	9

#	ARTICLE	IF	CITATIONS
299	Using Additional Information on Working Hours to Predict Coronary Heart Disease. <i>Annals of Internal Medicine</i> , 2011, 154, 457.	2.0	79
300	Decline in low-density lipoprotein cholesterol concentration: lipid-lowering drugs, diet, or physical activity? Evidence from the Whitehall II study. <i>Heart</i> , 2011, 97, 923-930.	1.2	37
301	The effect of eating habits on cardiovascular risk factors and the assessed cardiovascular risk. <i>Acta Alimentaria</i> , 2011, 40, 254-261.	0.3	4
302	The association between glucometabolic disturbances, traditional cardiovascular risk factors and self-rated health by age and gender: A cross-sectional analysis within the MalmÅ¶ Preventive Project. <i>Cardiovascular Diabetology</i> , 2011, 10, 118.	2.7	22
303	Interventions in primary care to improve cardiovascular risk factors and glycated haemoglobin (HbA1c) levels in patients with diabetes: a systematic review. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 479-489.	2.2	24
304	Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 458-466.	1.1	9
305	How do prescribing doctors anticipate the effect of statins?. <i>Journal of Evaluation in Clinical Practice</i> , 2011, 17, 420-428.	0.9	6
306	Self-Reported Cardiovascular Risk Factors in Immigrants and Swiss Nationals. <i>Public Health Nursing</i> , 2011, 28, 129-139.	0.7	12
307	Antihypertensive effectiveness of aliskiren for the "real-world" management of hypertension: multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study). <i>International Journal of Clinical Practice</i> , 2011, 65, 54-63.	0.8	14
308	Use of high-intensity statin therapy with simvastatin 80mg and atorvastatin 80mg in primary care. <i>International Journal of Clinical Practice</i> , 2011, 65, 120-126.	0.8	4
309	Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters. <i>European Journal of Clinical Nutrition</i> , 2011, 65, 247-254.	1.3	133
310	Benefits of smoking cessation with focus on cardiovascular and respiratory comorbidities. <i>Clinical Respiratory Journal</i> , 2011, 5, 187-194.	0.6	38
311	Tracking of Serum Lipid Levels, Blood Pressure, and Body Mass Index from Childhood to Adulthood: The Cardiovascular Risk in Young Finns Study. <i>Journal of Pediatrics</i> , 2011, 159, 584-590.	0.9	423
313	Effect of a cardiovascular prevention program on health behavior and BMI in highly educated adults: A randomized controlled trial. <i>Patient Education and Counseling</i> , 2011, 85, 122-126.	1.0	21
315	Adherence to a guideline on cardiovascular prevention: A comparison between general practitioners and practice nurses. <i>International Journal of Nursing Studies</i> , 2011, 48, 798-807.	2.5	29
316	Prediabetes: To treat or not to treat?. <i>European Journal of Pharmacology</i> , 2011, 672, 9-19.	1.7	25
319	National differences in screening programmes for cardiovascular risks could obstruct understanding of cardiovascular prevention studies in Europe. <i>Netherlands Heart Journal</i> , 2011, 19, 458-463.	0.3	1
320	Correlation between total cardiovascular risk and bone density in postmenopausal women. <i>Open Medicine (Poland)</i> , 2011, 6, 795-803.	0.6	4

#	ARTICLE	IF	CITATIONS
321	Testing an integrated model of the theory of planned behaviour and self-determination theory for different energy balance-related behaviours and intervention intensities. <i>British Journal of Health Psychology</i> , 2011, 16, 113-134.	1.9	61
322	Knowledge, attitudes, and behaviors of nursing professionals and students in Beijing toward cardiovascular disease risk reduction. <i>Research in Nursing and Health</i> , 2011, 34, 228-240.	0.8	13
323	Quality of diabetes care in Austrian diabetic patients willing to participate in a DMP " at baseline. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 436-443.	1.0	8
324	Occurrence of acute myocardial infarction in winter tourists: data from a retrospective questionnaire. <i>Clinical Research in Cardiology</i> , 2011, 100, 669-674.	1.5	19
327	Central Fat Influences Cardiac Autonomic Function in Obese and Overweight Girls. <i>Pediatric Cardiology</i> , 2011, 32, 924-928.	0.6	37
330	Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases. <i>EPMA Journal</i> , 2011, 2, 15-26.	3.3	15
331	The PANDORA study: peripheral arterial disease in patients with non-high cardiovascular risk. <i>Internal and Emergency Medicine</i> , 2011, 6, 509-519.	1.0	35
332	Developmental Mechanisms Involved in the Primary Prevention of Atherosclerosis and Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2011, 13, 170-175.	2.0	22
333	The High-Risk Plaque Initiative: Primary Prevention of Atherothrombotic Events in the Asymptomatic Population. <i>Current Atherosclerosis Reports</i> , 2011, 13, 359-366.	2.0	38
334	The Heinz Nixdorf Recall Study and Its Potential Impact on the Adoption of Atherosclerosis Imaging in European Primary Prevention Guidelines. <i>Current Atherosclerosis Reports</i> , 2011, 13, 367-372.	2.0	19
335	Incidence of cardiovascular events after kidney transplantation and cardiovascular risk scores: study protocol. <i>BMC Cardiovascular Disorders</i> , 2011, 11, 2.	0.7	30
336	Lipid-lowering drugs in ischaemic heart disease: A quasi-experimental uncontrolled before-and-after study of the effectiveness of clinical practice guidelines. <i>BMC Cardiovascular Disorders</i> , 2011, 11, 47.	0.7	2
337	Prevalence of peripheral arterial disease in subjects with moderate cardiovascular risk: Italian results from the PANDORA study Data from PANDORA (Prevalence of peripheral Arterial disease in) <i>Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 Cardiovascular Disorders</i> , 2011, 11, 59.	0.7	18
338	The effect of regular walks on various health aspects in older people with dementia: protocol of a randomized-controlled trial. <i>BMC Geriatrics</i> , 2011, 11, 38.	1.1	14
339	Efficacy of screening for high blood pressure in dental health care. <i>BMC Public Health</i> , 2011, 11, 194.	1.2	26
340	Peripheral and central arterial pressure and its relationship to vascular target organ damage in carotid artery, retina and arterial stiffness. Development and validation of a tool. The Vaso risk study. <i>BMC Public Health</i> , 2011, 11, 266.	1.2	17
341	Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. <i>BMC Public Health</i> , 2011, 11, 704.	1.2	28
342	Development and pilot of an internationally standardized measure of cardiovascular risk management in European primary care. <i>BMC Health Services Research</i> , 2011, 11, 70.	0.9	10

#	ARTICLE	IF	CITATIONS
343	Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2011, 10, 82.	2.7	12
344	Multidimensional prognostic indices for use in COPD patient care. A systematic review. <i>Respiratory Research</i> , 2011, 12, 151.	1.4	67
345	MAT-CHD _{SP} , a novel medication assessment tool for evaluation of secondary prevention of coronary heart disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 249-257.	0.9	12
346	Urinary proteomics in cardiovascular disease: Achievements, limits and hopes. <i>Proteomics - Clinical Applications</i> , 2011, 5, 222-232.	0.8	11
347	In vitro anti-platelet effects of simple plant-derived phenolic compounds are only found at high, non-physiological concentrations. <i>Molecular Nutrition and Food Research</i> , 2011, 55, 1624-1636.	1.5	50
348	Precision of a point of care testing device for lipid profiling. <i>European Journal of Lipid Science and Technology</i> , 2011, 113, 1230-1234.	1.0	2
349	Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. <i>Diabetes/Metabolism Research and Reviews</i> , 2011, 27, 362-372.	1.7	64
350	Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. <i>Clinical Biochemistry</i> , 2011, 44, 627-634.	0.8	3
351	Hypertension and angiogenesis in the aging kidney: A review. <i>Archives of Gerontology and Geriatrics</i> , 2011, 52, e93-e102.	1.4	13
352	Gender Differences in the Primary Prevention of Stroke with Aspirin. <i>Women's Health</i> , 2011, 7, 341-353.	0.7	9
353	Adequacy of reporting monitoring regimens of risk factors for cardiovascular disease in clinical guidelines: systematic review. <i>BMJ: British Medical Journal</i> , 2011, 342, d1289-d1289.	2.4	7
354	Red alert for women's heart: the urgent need for more research and knowledge on cardiovascular disease in women: Proceedings of the Workshop held in Brussels on Gender Differences in Cardiovascular disease, 29 September 2010. <i>European Heart Journal</i> , 2011, 32, 1362-1368.	1.0	245
355	Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2011, 13, 115-126.	2.9	318
356	Renoprotective effects of benazepril: current perspective. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 663-673.	0.6	3
357	Cardiorespiratory Fitness and Classification of Risk of Cardiovascular Disease Mortality. <i>Circulation</i> , 2011, 123, 1377-1383.	1.6	210
358	Does adding information on job strain improve risk prediction for coronary heart disease beyond the standard Framingham risk score? The Whitehall II study. <i>International Journal of Epidemiology</i> , 2011, 40, 1577-1584.	0.9	20
359	Intestinal sterol transporters and cholesterol absorption inhibition. <i>Current Opinion in Lipidology</i> , 2011, 22, 467-478.	1.2	24
360	The Global Burden of Cardiovascular Disease. <i>European Journal of Cardiovascular Nursing</i> , 2011, 10, S5-S13.	0.4	170

#	ARTICLE	IF	CITATIONS
361	Use of and Attitudes Toward Current Care Guidelines Among Primary and Secondary Care Nurses in Finland. <i>Clinical Nursing Research</i> , 2011, 20, 310-325.	0.7	9
362	New ESC/EAS Guidelines for the management of dyslipidaemias – any controversies behind the consensus?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 724-727.	3.1	13
364	Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 254-261.	3.1	18
365	Predicting CHD risk in France: a pooled analysis of the D.E.S.I.R., Three City, PRIME, and SU.VI.MAX studies. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 175-185.	3.1	17
366	A national survey on aspirin patterns of use and persistence in community outpatients in Italy. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 695-703.	3.1	14
367	Hyperpolarized Magnetic Resonance. <i>Circulation</i> , 2011, 124, 1580-1594.	1.6	120
368	Estimating the proportion of Danes at high risk of fatal cardiovascular disease. <i>Scandinavian Journal of Public Health</i> , 2011, 39, 571-576.	1.2	3
369	Significance of LDL-C lowering therapy in diabetic patients. <i>Clinical Lipidology</i> , 2011, 6, 389-399.	0.4	4
371	The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. <i>BMJ Open</i> , 2011, 1, e000363-e000363.	0.8	28
372	Individual and Population Benefits of Daily Aspirin Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 268-275.	0.9	30
373	Indexed left atrial volume predicts the recurrence of non-valvular atrial fibrillation after successful cardioversion. <i>European Journal of Echocardiography</i> , 2011, 12, 214-221.	2.3	73
374	Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. <i>European Heart Journal</i> , 2011, 32, 2143-2152.	1.0	285
375	Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. <i>European Heart Journal</i> , 2011, 32, 2962-2969.	1.0	36
376	Willingness to pay for a cardiovascular prevention program in highly educated adults: A randomized controlled trial. <i>International Journal of Technology Assessment in Health Care</i> , 2011, 27, 283-289.	0.2	8
377	Hypertension. <i>Circulation</i> , 2011, 123, 2892-2896.	1.6	80
378	The Association Between Dietary Sodium Intake, ESRD, and All-Cause Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2011, 34, 861-866.	4.3	301
379	Prevalence of cardiovascular risk factors and concentration of C-reactive protein in Type D personality persons without cardiovascular disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 504-509.	3.1	34
380	Effect of a tailored behavior change program on a composite lifestyle change score: a randomized controlled trial. <i>Health Education Research</i> , 2011, 26, 886-895.	1.0	22

#	ARTICLE	IF	CITATIONS
381	International data on supportive therapies at 1 year in acute coronary syndrome patients undergoing PCI: results from the APTOR study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 518-525.	3.1	6
382	Lipid-lowering effects of ezetimibe and simvastatin in combination. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 131-145.	0.6	14
383	Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 482-487.	0.5	434
384	Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 393-398.	3.1	127
385	Lifestyle consultation in general practice—the doctor's toolbox: a qualitative focus group study. <i>Family Practice</i> , 2011, 28, 220-225.	0.8	12
386	PSYCHOLOGICAL REACTIONS AND HEALTH BEHAVIOR FOLLOWING ACUTE MYOCARDIAL INFARCTION. <i>Acta Medica Medianae</i> , 2011, , 18-23.	0.0	1
387	Primary prevention of stroke: blood pressure, lipids, and heart failure. <i>European Heart Journal</i> , 2011, 32, 545-552.	1.0	76
388	Pitavastatin: finding its place in therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 101-117.	1.1	13
389	Management of Hypertension in the Elderly Patient at Abidjan Cardiology Institute (Ivory Coast). <i>International Journal of Hypertension</i> , 2012, 2012, 1-6.	0.5	7
390	Hypertension and antihypertensive treatment in HIV-infected individuals. A longitudinal cohort study. <i>Blood Pressure</i> , 2012, 21, 311-319.	0.7	28
391	Statins and noncardiac vascular disease. <i>Current Opinion in Cardiology</i> , 2012, 27, 392-397.	0.8	22
392	Inclusion of Stroke in Cardiovascular Risk Prediction Instruments. <i>Stroke</i> , 2012, 43, 1998-2027.	1.0	125
393	Cardiovascular risk age: concepts and practicalities. <i>Heart</i> , 2012, 98, 941-946.	1.2	60
394	Dietary energy density: a mediator of depressive symptoms and abdominal obesity or independent predictor of abdominal obesity?. <i>European Journal of Cardiovascular Nursing</i> , 2012, 11, 423-431.	0.4	15
395	How to Integrate Multiple Comorbidities in Guideline Development. <i>Proceedings of the American Thoracic Society</i> , 2012, 9, 274-281.	3.5	57
396	Blood pressure treatment target in patients with diabetes mellitus—current evidence. <i>Annals of Medicine</i> , 2012, 44, S36-S42.	1.5	8
397	Aerobic interval training compensates age related decline in cardiac function. <i>Scandinavian Cardiovascular Journal</i> , 2012, 46, 163-171.	0.4	56
398	Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. <i>Heart</i> , 2012, 98, 360-369.	1.2	184

#	ARTICLE	IF	CITATIONS
399	One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease. <i>Diabetes Care</i> , 2012, 35, 741-748.	4.3	38
400	Recording of risk-factors and lifestyle counselling in patients at high risk for cardiovascular diseases in European primary care. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 258-266.	0.8	36
401	Conflicts and dilemmas in prevention of cardiovascular disease. The new, Norwegian Guidelinesâ€™ a new approach to risk management. <i>European Journal of General Practice</i> , 2012, 18, 56-62.	0.9	2
402	Should identical CVD risks in young and old patients be managed identically? Results from two models. <i>BMJ Open</i> , 2012, 2, e000728.	0.8	7
404	Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease. <i>Clinical Medicine Insights: Cardiology</i> , 2012, 6, CMC.S4324.	0.6	94
405	CHANGES IN PSYCHOLOGICAL PARAMETERS AND HEALTH BEHAVIOR OF CORONARY AND NON-CORONARY PATIENTS FOLLOWING HOSPITALIZATION â€™ A SIX-MONTH FOLLOW-UP. <i>Acta Medica Medianae</i> , 2012, , 12-19.	0.0	1
406	Evidence-based exercise prescription: raising the standard of delivery. <i>International Musculoskeletal Medicine</i> , 2012, 34, 21-36.	0.1	1
407	Bridging the gap between public health and primary care in prevention of cardiometabolic diseases; background of and experiences with the Prevention Consultation in The Netherlands. <i>Family Practice</i> , 2012, 29, i126-i131.	0.8	20
408	Characteristics and Outcome in Acute Coronary Syndrome Patients with and without Established Modifiable Cardiovascular Risk Factors: Insights from the Nationwide AMIS Plus Registry 1997â€™2010. <i>Cardiology</i> , 2012, 121, 228-236.	0.6	10
409	Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach. <i>BMJ Open</i> , 2012, 2, e001029.	0.8	34
410	What components of chronic care organisation relate to better primary care for coronary heart disease patients? An observational study. <i>BMJ Open</i> , 2012, 2, e001344.	0.8	6
411	Clinical features of myocardial infarction and myocarditis in young adults: a retrospective study. <i>BMJ Open</i> , 2012, 2, e001571.	0.8	10
412	Home-based cardiac rehabilitation is an attractive alternative to no cardiac rehabilitation for elderly patients with coronary heart disease: results from a randomised clinical trial. <i>BMJ Open</i> , 2012, 2, e001820.	0.8	55
414	Fixed-dose combination therapy for the prevention of cardiovascular disease. , 2012, , .		1
415	Relation between adiposity and hypertension persists after onset of clinically manifest arterial disease. <i>Journal of Hypertension</i> , 2012, 30, 2331-2337.	0.3	9
416	High-density lipoprotein levels and risk of cardiovascular events. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 575-586.	0.6	22
418	Fibrates for primary prevention of cardiovascular disease events. , 2012, , .		8
420	Chest pain presentation in women and the psychological impact. <i>British Journal of Cardiac Nursing</i> , 2012, 7, 58-65.	0.0	2

#	ARTICLE	IF	CITATIONS
421	Relationship of a Low Ankle-brachial Index with All-cause Mortality and Cardiovascular Mortality in Chinese Patients with Metabolic Syndrome after a 6-Year Follow-up: A Chinese Prospective Cohort Study. <i>Internal Medicine</i> , 2012, 51, 2847-2856.	0.3	10
422	The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. <i>Lancet, The</i> , 2012, 380, 581-590.	6.3	2,250
423	Personality profiles and health: Longitudinal evidence among Finnish adults. <i>Scandinavian Journal of Psychology</i> , 2012, 53, 512-522.	0.8	56
424	Maximizing Therapeutic Envelope for Prevention of Cardiovascular Disease: Role of Polypill. <i>Mount Sinai Journal of Medicine</i> , 2012, 79, 683-688.	1.9	5
425	Aspirin for Primary Prevention of Cardiovascular Disease Events. <i>Pharmacotherapy</i> , 2012, 32, 1020-1035.	1.2	34
426	Ankle-brachial index and cardiovascular risk prediction: An analysis of 11,594 individuals with 10-year follow-up. <i>Atherosclerosis</i> , 2012, 220, 160-167.	0.4	60
427	Assessment of the value of a genetic risk score in improving the estimation of coronary risk. <i>Atherosclerosis</i> , 2012, 222, 456-463.	0.4	50
428	A simple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE. <i>Atherosclerosis</i> , 2012, 222, 564-566.	0.4	9
429	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>Atherosclerosis</i> , 2012, 223, 1-68.	0.4	414
430	Subclinical vascular disease in patients with systemic lupus erythematosus: The additive deleterious effect of the antiphospholipid syndrome. <i>Joint Bone Spine</i> , 2012, 79, 628-629.	0.8	4
431	New "European Association of Psychosomatic Medicine"™ founded. <i>Journal of Psychosomatic Research</i> , 2012, 73, 343-344.	1.2	6
432	Magnitude and Management of Hypercholesterolemia in the Adult Population of Spain, 2008-2010: The ENRICA Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 551-558.	0.4	35
433	The Worldwide Environment of Cardiovascular Disease: Prevalence, Diagnosis, Therapy, and Policy Issues. <i>Journal of the American College of Cardiology</i> , 2012, 60, S1-S49.	1.2	631
434	«Fisiologia da inatividade», um novo paradigma para entender os efeitos benéficos da prática regular de exercício físico em doenças metabólicas. <i>Revista Portuguesa De Endocrinologia Diabetes E Metabolismo</i> , 2012, 7, 36-43.	0.1	0
436	Ácido Úrico como factor de riesgo cardiovascular. <i>Hipertension Y Riesgo Vascular</i> , 2012, 29, 36-43.	0.3	0
438	Resting heart rate and incident heart failure in apparently healthy men and women in the EPIC-Norfolk study. <i>European Journal of Heart Failure</i> , 2012, 14, 1163-1170.	2.9	31
440	Daily and intermittent rosuvastatin 5%mg therapy in statin intolerant patients: an observational study. <i>Current Medical Research and Opinion</i> , 2012, 28, 371-378.	0.9	45
441	Ezetimibe/Simvastatin: A Guide to its Clinical Use in Hypercholesterolemia. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 49-56.	1.0	12

#	ARTICLE	IF	CITATIONS
442	Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. <i>European Heart Journal</i> , 2012, 33, 2865-2872.	1.0	59
443	Improved Identification and Antihypertension Pharmacotherapy in Cardiorenal Metabolic Syndrome: Focus on Racial/Ethnic Minorities, Olmesartan Medoxomil, and Combination Therapy. <i>CardioRenal Medicine</i> , 2012, 2, 256-267.	0.7	1
444	Patients'™ experiences with symptoms and needs in the early rehabilitation phase after coronary artery bypass grafting. <i>European Journal of Cardiovascular Nursing</i> , 2012, 11, 14-24.	0.4	52
445	Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1496-1501.	0.5	38
446	Magnitud y manejo de la hipercolesterolemia en la poblaci3n adulta de Espa±a, 2008-2010: el estudio ENRICA. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 551-558.	0.6	127
447	How many patients need statin treatment in a low-cardiovascular-risk country? Low-density lipoprotein-cholesterol target and distance from target distribution in an Italian cohort. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 327-336.	1.1	13
448	The effect of low-dose marine n-3 fatty acids on the biosynthesis of pro-inflammatory 5-lipoxygenase pathway metabolites in overweight subjects: A randomized controlled trial. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2012, 87, 43-48.	1.0	20
449	Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 163-174.	1.0	32
452	Increased pulse wave velocity in patients with panic disorder: Independent vascular influence of panic disorder on arterial stiffness. <i>Journal of Psychosomatic Research</i> , 2012, 73, 145-148.	1.2	28
454	Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40±80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5±10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies. <i>Current Therapeutic Research</i> , 2012, 73, 65-84.	0.5	8
455	Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012, 98, 83-90.	1.1	18
456	Aragon workers'™ health study – design and cohort description. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 45.	0.7	70
457	The effects of Hartcoach, a life style intervention provided by telephone on the reduction of coronary risk factors: a randomised trial. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 47.	0.7	14
458	E-Rehabilitation – an Internet and mobile phone based tailored intervention to enhance self-management of Cardiovascular Disease: study protocol for a randomized controlled trial. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 50.	0.7	29
459	Applicability of the ankle-brachial-index measurement as screening device for high cardiovascular risk: an observational study. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 59.	0.7	14
460	The effect of a comprehensive lifestyle intervention on cardiovascular risk factors in pharmacologically treated patients with stable cardiovascular disease compared to usual care: a randomised controlled trial. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 71.	0.7	27
461	Cardiovascular risk management in patients with coronary heart disease in primary care: variation across countries and practices. An observational study based on quality indicators. <i>BMC Family Practice</i> , 2012, 13, 96.	2.9	17
462	Perceived need to increase physical activity levels among adults at high risk of type 2 diabetes. A cross-sectional analysis within a community-based diabetes prevention project FIN-D2D. <i>BMC Public Health</i> , 2012, 12, 514.	1.2	14

#	ARTICLE	IF	CITATIONS
463	Self-reported leisure time physical activity: a useful assessment tool in everyday health care. <i>BMC Public Health</i> , 2012, 12, 693.	1.2	94
464	The association of leisure-time physical activity and active commuting with measures of socioeconomic position in a multiethnic population living in the Netherlands: results from the cross-sectional SUNSET study. <i>BMC Public Health</i> , 2012, 12, 815.	1.2	18
465	Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. <i>Cardiovascular Diabetology</i> , 2012, 11, 122.	2.7	99
466	Lactation and cardiovascular risk factors in mothers in a population-based study: the HUNT-study. <i>International Breastfeeding Journal</i> , 2012, 7, 8.	0.9	66
467	Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial. <i>BMC Research Notes</i> , 2012, 5, 251.	0.6	10
468	Progression of Subclinical Myocardial Dysfunction in Type 2 Diabetes after 5 years Despite Improved Glycemic Control. <i>Echocardiography</i> , 2012, 29, 1045-1053.	0.3	17
469	Pitavastatin. <i>Drugs</i> , 2012, 72, 565-584.	4.9	27
471	French Society of Cardiology guidelines for cardiac rehabilitation in adults. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 309-328.	0.7	91
472	Role of omega-3 ethyl ester concentrate in reducing sudden cardiac death following myocardial infarction and in management of hypertriglyceridemia: An Indian consensus statement. <i>Indian Heart Journal</i> , 2012, 64, 503-507.	0.2	2
473	Vascular Risk Status as a Predictor of Later-Life Depressive Symptoms: A Cohort Study. <i>Biological Psychiatry</i> , 2012, 72, 324-330.	0.7	34
474	Effect of a combined nutraceutical containing Orthosiphon stamineus effect on blood pressure and metabolic syndrome components in hypertensive dyslipidaemic patients: A randomized clinical trial. <i>Complementary Therapies in Clinical Practice</i> , 2012, 18, 190-194.	0.7	19
475	Complicaciones macrovasculares del paciente diabético. <i>Medicine</i> , 2012, 11, 1011-1020.	0.0	0
476	Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: Results from VOYAGER. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 697-703.	1.1	14
477	Exercise in Cardiovascular Diseases. <i>PM and R</i> , 2012, 4, 867-873.	0.9	26
482	Does Orthopaedic Surgical Training Induce Hypertension? A Pilot Study. <i>Clinical Orthopaedics and Related Research</i> , 2012, 470, 3253-3260.	0.7	7
484	Cardiovascular risk management of hypertension and hypercholesterolaemia in the Netherlands: from unifactorial to multifactorial approach. <i>Netherlands Heart Journal</i> , 2012, 20, 320-325.	0.3	15
485	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). <i>International Journal of Behavioral Medicine</i> , 2012, 19, 403-488.	0.8	224
486	Comentarios a la guía de práctica clínica de la ESC sobre prevención de la enfermedad cardiovascular (versión 2012). Un informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología. <i>Revista Española De Cardiología</i> , 2012, 65, 869-873.	0.6	22

#	ARTICLE	IF	CITATIONS
487	Comments on the ESC Guidelines on Cardiovascular Disease Prevention (Version 2012). A Report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 869-873.	0.4	2
488	Update on guidelines for management of hypercholesterolemia. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1239-1249.	0.6	5
489	Critical review: vegetables and fruit in the prevention of chronic diseases. <i>European Journal of Nutrition</i> , 2012, 51, 637-663.	1.8	1,320
490	Targeting the IKK β /mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2212-2221.	1.9	31
491	Aerobic interval training reduces blood pressure and improves myocardial function in hypertensive patients. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 151-160.	0.8	254
492	Identifying factors associated with experiences of coronary heart disease patients receiving structured chronic care and counselling in European primary care. <i>BMC Health Services Research</i> , 2012, 12, 221.	0.9	20
493	Power and powerlessness: GPs' narratives about lifestyle counselling. <i>British Journal of General Practice</i> , 2012, 62, e160-e166.	0.7	8
494	Barriers to cardiovascular risk prevention and management in Germany – an analysis of the EURIKA study. <i>Vascular Health and Risk Management</i> , 2012, 8, 177.	1.0	13
495	Accuracy of the ankle-brachial index using the SCVL®, an arm and ankle automated device with synchronized cuffs, in a population with increased cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2012, 8, 239.	1.0	10
496	Long-Term Arterial Adaptation to High Blood Flow in the Feeding Artery of Vascular Access for Hemodialysis. <i>Journal of Vascular Access</i> , 2012, 13, 305-309.	0.5	7
497	Genetic variations of HSPA1A, the heat shock protein levels, and risk of atherosclerosis. <i>Cell Stress and Chaperones</i> , 2012, 17, 507-516.	1.2	20
498	The role of aspirin in cancer prevention. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 259-267.	12.5	424
499	The Assessment of Endothelial Function. <i>Circulation</i> , 2012, 126, 753-767.	1.6	952
500	Lipid apheresis: oxidative stress, rheology, and vasodilatation. <i>Clinical Research in Cardiology Supplements</i> , 2012, 7, 45-49.	2.0	17
502	Attainment of Normal Lipid Levels Among Patients on Lipid-Modifying Therapy in Hong Kong. <i>Advances in Therapy</i> , 2012, 29, 427-441.	1.3	6
503	Cardiovascular Risk Factor Assessments and Health Behaviours in Patients Using Statins Compared to a Non-Treated Population. <i>International Journal of Behavioral Medicine</i> , 2012, 19, 134-142.	0.8	20
505	Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 58-64.	0.7	18
506	Indexed Left Atrial Volume Is Superior to Left Atrial Diameter in Predicting Nonvalvular Atrial Fibrillation Recurrence after Successful Cardioversion: A Prospective Study. <i>Echocardiography</i> , 2012, 29, 276-284.	0.3	47

#	ARTICLE	IF	CITATIONS
507	New directions in cardiovascular risk assessment: the role of secondary risk stratification markers. <i>International Journal of Clinical Practice</i> , 2012, 66, 622-630.	0.8	22
508	Prognostic Impact of Baseline Low Blood Pressure in Hypertensive Patients With Stable Coronary Artery Disease of Daily Clinical Practice. <i>Journal of Clinical Hypertension</i> , 2012, 14, 537-546.	1.0	7
509	Differences in markers of cardiovascular disease between professional football players of West-Asian and Black African descent. <i>Journal of Science and Medicine in Sport</i> , 2012, 15, 266-271.	0.6	7
510	Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice. <i>Respirology</i> , 2012, 17, 422-431.	1.3	69
511	Type D personality is associated with impaired psychological status and unhealthy lifestyle in Icelandic cardiac patients: A cross-sectional study. <i>BMC Public Health</i> , 2012, 12, 42.	1.2	35
513	Levels and trends in cardiovascular risk factors and drug treatment in 4837 elderly Dutch myocardial infarction patients between 2002 and 2006. <i>Netherlands Heart Journal</i> , 2012, 20, 102-109.	0.3	9
514	Atherosclerosis Screening by Noninvasive Imaging for Cardiovascular Prevention: A Systematic Review. <i>Journal of General Internal Medicine</i> , 2012, 27, 220-231.	1.3	17
515	Do cardiovascular disease risk prediction tools need to be updated in Europe?. <i>Internal and Emergency Medicine</i> , 2012, 7, 95-95.	1.0	0
516	The prevalence and management of cardiovascular risk factors in immigrant groups in Switzerland. <i>International Journal of Public Health</i> , 2012, 57, 63-77.	1.0	7
520	Myocardial perfusion imaging: a plus for coronary risk classification in diabetics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 383-386.	3.3	1
521	Providing cardiovascular risk management information to acute coronary syndrome patients: A randomized trial. <i>British Journal of Health Psychology</i> , 2013, 18, 83-96.	1.9	19
522	Prevalence rate of Metabolic Syndrome in a group of light and heavy smokers. <i>Diabetology and Metabolic Syndrome</i> , 2013, 5, 28.	1.2	30
523	Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathways. <i>BMC Research Notes</i> , 2013, 6, 52.	0.6	7
524	Cardiovascular disease in autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2013, 12, 1004-1015.	2.5	232
525	Application of the MAT-CHDSP to assess guideline adherence and therapy goal achievement in secondary prevention of coronary heart disease after percutaneous coronary intervention. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 703-709.	0.8	13
526	Comparing the effectiveness of two cardiovascular prevention programmes for highly educated professionals in general practice: a randomised clinical trial. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 38.	0.7	8
527	Cardiometabolic prevention consultation in the Netherlands: screening uptake and detection of cardiometabolic risk factors and diseases – a pilot study. <i>BMC Family Practice</i> , 2013, 14, 29.	2.9	32
528	Evaluating an implementation strategy in cardiovascular prevention to improve prescribing of statins in Germany: an intention to treat analysis. <i>BMC Public Health</i> , 2013, 13, 623.	1.2	5

#	ARTICLE	IF	CITATIONS
529	Pharmacological primary and secondary cardiovascular prevention among diabetic patients in a multiethnic general practice population: still room for improvements. BMC Health Services Research, 2013, 13, 182.	0.9	7
530	Economic efficiency of primary care for CVD prevention and treatment in Eastern European countries. BMC Health Services Research, 2013, 13, 75.	0.9	5
531	Postprandial effect of dietary fat quantity and quality on arterial stiffness and wave reflection: a randomised controlled trial. Nutrition Journal, 2013, 12, 93.	1.5	28
532	Detection of Early Left Ventricular and Atrial Dysfunction in Overweight Patients with Preserved Ejection Fraction: A Speckle Tracking Analysis. Echocardiography, 2013, 30, 551-557.	0.3	8
533	Assessment of lipid-lowering treatment in Bulgaria – The CEPHEUS study. Open Medicine (Poland), 2013, 8, 627-637.	0.6	1
535	Physical activity and type 2 diabetes. Recommendations of the SFD (Francophone Diabetes Society) diabetes and physical activity working group. Diabetes and Metabolism, 2013, 39, 205-216.	1.4	64
536	The risk of atherosclerosis in patients with chronic kidney disease. International Urology and Nephrology, 2013, 45, 1605-1612.	0.6	76
537	Prognostic value of cardiovascular disease status: the Leiden 85-plus study. Age, 2013, 35, 1433-1444.	3.0	16
538	Are the elderly different?. Zeitschrift Fur Gerontologie Und Geriatrie, 2013, 46, 144-150.	0.8	4
539	Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 799-807.	1.1	111
540	Prevençã³n secundaria en el paciente coronario. EMC - Tratado De Medicina, 2013, 17, 1-8.	0.0	0
541	Strategies for preventing type 2 diabetes: an update for clinicians. Therapeutic Advances in Chronic Disease, 2013, 4, 242-261.	1.1	45
542	InVivo assessment of endothelial function in human lower extremity arteries. Journal of Vascular Surgery, 2013, 58, 1259-1266.	0.6	12
543	How useful are hypertension guidelines for diabetes?. Diabetes Management, 2013, 3, 115-121.	0.5	0
544	Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia. American Journal of Cardiology, 2013, 112, 1885-1895.	0.7	45
545	Medication assessment tool to detect care issues from routine data: a pilot study in primary care. International Journal of Clinical Pharmacy, 2013, 35, 1063-1074.	1.0	9
546	Pitavastatin in cardiometabolic disease: therapeutic profile. Cardiovascular Diabetology, 2013, 12, S2.	2.7	21
547	Preclinical atherosclerosis and metabolic syndrome increase cardio- and cerebrovascular events rate: a 20-year follow up. Cardiovascular Diabetology, 2013, 12, 155.	2.7	37

#	ARTICLE	IF	CITATIONS
548	Increased Pulse Wave Velocity and Carotid Intima-Media Thickness in Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2293-2300.	1.1	26
549	The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies. <i>Pharmacoeconomics</i> , 2013, 31, 445-454.	1.7	6
550	Primary care of patients with high cardiovascular risk. <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 371-380.	1.0	3
551	Non-dipping pattern in untreated hypertensive patients is related to increased pulse wave velocity independent of raised nocturnal blood pressure. <i>Blood Pressure</i> , 2013, 22, 34-38.	0.7	32
552	Chapter 5: Referral to specialists and models of care. <i>Kidney International Supplements</i> , 2013, 3, 112-119.	4.6	38
553	Associations between Borg's rating of perceived exertion and physiological measures of exercise intensity. <i>European Journal of Applied Physiology</i> , 2013, 113, 147-155.	1.2	489
554	Hypertension Risk Assessment in the Largest Ethnic Groups in Jordan. <i>Journal of Immigrant and Minority Health</i> , 2013, 15, 43-48.	0.8	13
555	Oxidative stress in patients with essential hypertension: A comparison of dippers and non-dippers. <i>European Journal of Internal Medicine</i> , 2013, 24, 139-144.	1.0	29
556	A Novel Approach to Cardiovascular Health By Optimizing Risk Management (ANCHOR): Behavioural Modification in Primary Care Effectively Reduces Global Risk. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1400-1407.	0.8	18
557	Effects of n-3 polyunsaturated fatty acids on depressive symptoms, anxiety and emotional state in patients with acute myocardial infarction. <i>Pharmacological Reports</i> , 2013, 65, 59-68.	1.5	31
558	The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. <i>Atherosclerosis</i> , 2013, 228, 18-28.	0.4	119
560	Left ventricular hypertrophy reduction and clinical events. A meta-regression analysis of 14 studies in 12,809 hypertensive patients. <i>International Journal of Cardiology</i> , 2013, 167, 2757-2764.	0.8	26
561	Myocardial perfusion and intima-media thickness in patients with subclinical hypothyroidism. <i>Advances in Medical Sciences</i> , 2013, 58, 44-49.	0.9	12
562	Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: Results from the antiplatelet treatment observational registries (APTOR). <i>International Journal of Cardiology</i> , 2013, 170, 239-245.	0.8	16
563	Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study. <i>International Journal of Cardiology</i> , 2013, 166, 210-214.	0.8	12
564	n-3 PUFAs in cardiovascular disease. <i>International Journal of Cardiology</i> , 2013, 170, S33-S38.	0.8	21
565	Non-obstructive coronary artery disease documented by cardiac computed tomography: Discrepancy between atherosclerotic burden and cardiovascular risk. <i>Revista Portuguesa De Cardiologia (English)</i> 2013, 32, 107-111.	0.8	10
566	Cardiology for gynecologists: A minireview. <i>Maturitas</i> , 2013, 75, 386-391.	1.0	3

#	ARTICLE	IF	CITATIONS
567	Attainment of normal lipid levels among high cardiovascular risk patients: Pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada. <i>European Journal of Internal Medicine</i> , 2013, 24, 656-663.	1.0	7
568	Subclinical atherosclerosis in menopausal women with low to medium calculated cardiovascular risk. <i>International Journal of Cardiology</i> , 2013, 164, 70-76.	0.8	33
570	Physician characteristics and prescription drug use during pregnancy: a population-based study. <i>Annals of Epidemiology</i> , 2013, 23, 54-59.	0.9	3
571	L'absence d'alcool et le paradoxe français. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2013, 2013, 36-41.	0.0	0
572	Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study). <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 124-134.	0.7	0
573	Family History of Cardiovascular Disease and Offspring Echocardiographic Left Ventricular Structure and Function: The Asklepios Study. <i>Journal of the American Society of Echocardiography</i> , 2013, 26, 1290-1297.e2.	1.2	4
574	Prevention of Coronary Artery Disease: Recent Advances in the Management of Hypertension. <i>Current Atherosclerosis Reports</i> , 2013, 15, 311.	2.0	6
575	Slovak Trial on Cardiovascular Risk Reduction Following National Guidelines with CaDUETÂ® (The Tj ETQq1 1 0.784314 rgBT/Overlock 1.3 6	1.3	6
576	The NAILED stroke risk factor trial (Nurse based Age independent Intervention to Limit Evolution of) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 5	0.7	13
578	Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70Âmg/dl or a 50% reduction in high-risk patients: Results from VOYAGER. <i>Atherosclerosis</i> , 2013, 228, 265-269.	0.4	20
579	Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia. <i>Diabetology International</i> , 2013, 4, 117-125.	0.7	5
580	Comparison of body composition, basal metabolic rate and metabolic outcomes of adults with Prader Willi syndrome or lesional hypothalamic disease, with primary obesity. <i>International Journal of Obesity</i> , 2013, 37, 1198-1203.	1.6	32
581	Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. <i>Kidney International Supplements</i> , 2013, 3, 91-111.	4.6	38
583	Personalized cardiovascular medicine: concepts and methodological considerations. <i>Nature Reviews Cardiology</i> , 2013, 10, 308-316.	6.1	32
584	Is walking to school associated with improved metabolic health?. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2013, 10, 12.	2.0	58
585	Oral Antithrombotic Therapy in Atrial Fibrillation Associated With Acute or Chronic Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2013, 29, S60-S70.	0.8	11
586	Use and indications of cholestyramine and bile acid sequestrants. <i>Internal and Emergency Medicine</i> , 2013, 8, 205-210.	1.0	75
587	EMAS position statement: Diet and health in midlife and beyond. <i>Maturitas</i> , 2013, 74, 99-104.	1.0	39

#	ARTICLE	IF	CITATIONS
588	Intima-Media Thickness in Severe Obesity. <i>Diabetes Care</i> , 2013, 36, 3793-3802.	4.3	26
589	<scp>PKPD</scp> modelling of the interrelationship between mean arterial <scp>BP</scp>, cardiac output and total peripheral resistance in conscious rats. <i>British Journal of Pharmacology</i> , 2013, 169, 1510-1524.	2.7	25
590	Attainment of Goal and Normalized Lipid Levels With Lipid-Modifying Therapy in Malaysia. <i>Clinical Therapeutics</i> , 2013, 35, 450-460.	1.1	1
592	Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 549-554.	0.8	24
593	Use of Antiplatelet Agents in Patients With Atherosclerotic Disease. <i>Postgraduate Medicine</i> , 2013, 125, 19-30.	0.9	2
594	Chapter 2: Pharmacological cholesterol-lowering treatment in adults. <i>Kidney International Supplements</i> , 2013, 3, 271-279.	4.6	16
595	Effect of cocoa and theobromine consumption on serum HDL-cholesterol concentrations: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2013, 97, 1201-1209.	2.2	90
596	Associations of job strain and lifestyle risk factors with risk of coronary artery disease: a meta-analysis of individual participant data. <i>Cmaj</i> , 2013, 185, 763-769.	0.9	95
597	Benchmarking progress in the implementation of the Fourth Joint Societiesâ€™ Task Force Guidelines on the Prevention of Cardiovascular Disease in Clinical Practice. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 54-60.	0.8	4
598	Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 29-39.	0.8	13
599	Growth Hormone Therapy for Children and Adolescents with Prader-Willi Syndrome Is Associated with Improved Body Composition and Metabolic Status in Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E328-E335.	1.8	54
600	RTN4 AND FBXL17 GENES ARE ASSOCIATED WITH CORONARY HEART DISEASE IN GENOME-WIDE ASSOCIATION ANALYSIS OF LITHUANIAN FAMILIES. <i>Balkan Journal of Medical Genetics</i> , 2013, 16, 17-22.	0.5	14
601	Where you live matters: Challenges and opportunities to address the urbanâ€™rural divide through innovative secondary cardiac rehabilitation programs. <i>Australian Journal of Rural Health</i> , 2013, 21, 170-177.	0.7	14
602	Effect of Cardiovascular Training on Fitness and Perceived Disease Activity in People With Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , 2013, 65, 1844-1852.	1.5	61
603	Increased pulse wave velocity and carotid intimaâ€™media thickness in patients with carpal tunnel syndrome. <i>Muscle and Nerve</i> , 2013, 47, 872-877.	1.0	6
604	Nonâ€™HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the <scp>EPIC</scp>â€™Norfolk prospective population study. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1009-1015.	1.7	27
605	A multicomponent lifestyle intervention produces favourable changes in diet quality and cardiometabolic risk indices in hypercholesterolaemic adults. <i>Journal of Human Nutrition and Dietetics</i> , 2013, 26, 596-605.	1.3	14
606	Factors that influence obesity, functional capacity, anxiety and depression outcomes following a Phase <scp>III</scp> cardiac rehabilitation programme. <i>Journal of Clinical Nursing</i> , 2013, 22, 2758-2767.	1.4	12

#	ARTICLE	IF	CITATIONS
607	Feasibility and Effectiveness in Clinical Practice of a Multifactorial Intervention for the Reduction of Cardiovascular Risk in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2566-2572.	4.3	20
608	Comment on "Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors". <i>British Journal of Cancer</i> , 2013, 109, 2502-2503.	2.9	1
609	Reply: "Comment on Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors". <i>British Journal of Cancer</i> , 2013, 109, 2503-2504.	2.9	1
610	Moderate overweight is beneficial and severe obesity detrimental for patients with documented atherosclerotic heart disease. <i>Heart</i> , 2013, 99, 655-660.	1.2	62
611	Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. <i>BMJ</i> , The, 2013, 347, f6008-f6008.	3.0	199
612	Total Lipid Management and Cardiovascular Disease in the Dyslipidemia International Study. <i>Cardiology</i> , 2013, 125, 154-163.	0.6	18
613	Development and evaluation of a brief self-completed family history screening tool for common chronic disease prevention in primary care. <i>British Journal of General Practice</i> , 2013, 63, e393-e400.	0.7	24
614	Comparison of cardiovascular risk calculation tools in pharmacy practice. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2013, 53, 408-413.	0.7	5
615	Arterial stiffness changes in patients with cardiovascular risk factors but normal carotid intima-media thickness. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 622-628.	0.6	13
616	Hypertensive target organ damage and the risk for vascular events and all-cause mortality in patients with vascular disease. <i>Journal of Hypertension</i> , 2013, 31, 492-500.	0.3	31
617	Dyslipidemia, Kidney Disease, and Cardiovascular Disease in Diabetic Patients. <i>Review of Diabetic Studies</i> , 2013, 10, 88-100.	0.5	89
618	Effects of ACE polymorphisms and other risk factors on the severity of coronary artery disease. <i>Genetics and Molecular Research</i> , 2013, 12, 6895-6906.	0.3	34
619	Effects of irregular-shift work and physical activity on cardiovascular risk factors in truck drivers. <i>Revista De Saude Publica</i> , 2013, 47, 497-505.	0.7	32
620	Effectiveness of a quality improvement intervention targeting cardiovascular risk factors: are patients responsive to information and encouragement by mail or post?. <i>Vascular Health and Risk Management</i> , 2013, 9, 13.	1.0	18
621	Population Specific and Up to Date Cardiovascular Risk Charts Can Be Efficiently Obtained with Record Linkage of Routine and Observational Data. <i>PLoS ONE</i> , 2013, 8, e56149.	1.1	1
622	Achievement of Cardiometabolic Goals among Diabetic Patients in Spain. A Nationwide Population-Based Study. <i>PLoS ONE</i> , 2013, 8, e61549.	1.1	30
623	Addition of a Novel, Protective Family History Category Allows Better Profiling of Cardiovascular Risk and Atherosclerotic Burden in the General Population. <i>The Asklepios Study</i> . <i>PLoS ONE</i> , 2013, 8, e63185.	1.1	7
624	Stress and cardiovascular disease. <i>Journal of the Korean Medical Association</i> , 2013, 56, 462.	0.1	9

#	ARTICLE	IF	CITATIONS
625	Physical activity in the prevention of peripheral artery disease in the elderly. <i>Frontiers in Physiology</i> , 2014, 5, 12.	1.3	15
626	Endothelial function testing and cardiovascular disease: focus on peripheral arterial tonometry. <i>Vascular Health and Risk Management</i> , 2014, 10, 577.	1.0	55
627	High-Intensity Intermittent Exercise Training for Cardiovascular Disease. <i>Journal of Novel Physiotherapies</i> , 2014, 04, .	0.1	4
629	Periodontal Disease, Atherosclerosis, Adverse Pregnancy Outcomes, and Head-and-Neck Cancer. <i>Advances in Dental Research</i> , 2014, 26, 47-55.	3.6	70
630	Is the 6-minute cycle test useful in a cardiac rehabilitation programme?. <i>European Journal of Physiotherapy</i> , 2014, 16, 17-24.	0.7	0
631	The remote exercise monitoring trial for exercise-based cardiac rehabilitation (REMOTE-CR): a randomised controlled trial protocol. <i>BMC Public Health</i> , 2014, 14, 1236.	1.2	28
632	Dietary Hyperlipidemia and Retinal Microaneurysms. , 2014, , 613-618.		0
633	Implementing Best Practice in Psoriasis: A Nordic Expert Group Consensus. <i>Acta Dermato-Venereologica</i> , 2014, 94, 547-552.	0.6	13
634	Effect of an intervention to improve the cardiovascular health of family members of patients with coronary artery disease: a randomized trial. <i>Cmaj</i> , 2014, 186, 23-30.	0.9	24
635	Postprandial lipemia as a cardiometabolic risk factor. <i>Current Medical Research and Opinion</i> , 2014, 30, 1489-1503.	0.9	94
636	Treat-to-target trials in diabetes. <i>Indian Journal of Endocrinology and Metabolism</i> , 2014, 18, 166.	0.2	19
637	Which lipid measurement should we monitor? An analysis of the LIPID study. <i>BMJ Open</i> , 2014, 4, e003512.	0.8	12
638	Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. <i>Haematologica</i> , 2014, 99, 1197-1203.	1.7	114
639	Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea. <i>BMC Health Services Research</i> , 2014, 14, 100.	0.9	15
640	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: Prognosis and implications for short- and long-term management. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 395-409.	0.9	15
641	Introduction of HDL Molecules, Past and Brief Future. , 2014, , 1-8.		0
642	Who Needs Laboratories and Who Needs Statins?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 25-32.	0.9	23
643	Dietary fiber intake and mortality among survivors of myocardial infarction: prospective cohort study. <i>BMJ, The</i> , 2014, 348, g2659-g2659.	3.0	41

#	ARTICLE	IF	CITATIONS
644	Carotid Artery Stenting: Second Consensus Document of the ICCS/ISO-SPREAD Joint Committee. <i>Cerebrovascular Diseases</i> , 2014, 38, 77-93.	0.8	9
645	Assessing Depression in Cardiac Patients: What Measures Should Be Considered?. <i>Depression Research and Treatment</i> , 2014, 2014, 1-17.	0.7	38
646	Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia. <i>Angiology</i> , 2014, 65, 919-926.	0.8	27
647	SURF – Survey of Risk Factor management: first report of an international audit. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 813-822.	0.8	19
648	Circulating progenitor cells in rheumatoid arthritis: association with inflammation and oxidative stress. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 184-193.	0.6	28
649	Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. <i>Annals of Medicine</i> , 2014, 46, 155-162.	1.5	27
650	The evaluation of selected shellfish as a source of niacin in nutrition and therapy of modern human. <i>Polish Annals of Medicine</i> , 2014, 21, 14-19.	0.3	4
651	Heated water-based exercise training reduces 24-hour ambulatory blood pressure levels in resistant hypertensive patients: A randomized controlled trial (HEX trial). <i>International Journal of Cardiology</i> , 2014, 172, 434-441.	0.8	82
652	Cytokines and hs-CRP levels in individuals treated with low-dose aspirin for cardiovascular prevention: A population-based study (CoLaus Study). <i>Cytokine</i> , 2014, 66, 95-100.	1.4	22
653	Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 363-369.	1.1	3
655	Which statin worked best to achieve lipid level targets in a European registry? A post-hoc analysis of the EUROASPIRE III for coronary heart disease patients. <i>Journal of the Saudi Heart Association</i> , 2014, 26, 183-191.	0.2	12
656	Effect of Sustaining Lifestyle Modifications (Nonsmoking, Weight Reduction, Physical Activity, and) Tj ETQq1 1 0.784314 rgBT /Overlo Bypass (from the REasons for Geographic and Racial Differences in Stroke Study). <i>American Journal of Cardiology</i> , 2014, 113, 1933-1940.	0.7	104
657	Perceived Sufficiency of Physical Activity Levels Among Adults at High Risk of Type 2 Diabetes: The FIN-D2D Study. <i>International Journal of Behavioral Medicine</i> , 2014, 21, 99-108.	0.8	5
658	Secular trends in serum lipid levels of a Middle Eastern adult population; 10 years follow up in Tehran lipid and glucose study. <i>Lipids in Health and Disease</i> , 2014, 13, 20.	1.2	30
659	Serum Cholesterol by Morbidly Obese Patients after Laparoscopic Sleeve Gastrectomy and Additional Physical Activity. <i>Obesity Surgery</i> , 2014, 24, 385-389.	1.1	22
660	Caloric restriction or telmisartan control dyslipidemia and nephropathy in obese diabetic Z ^{1/4} cker rats. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 10.	1.2	7
661	Are lower urinary tract symptoms in men associated with cardiovascular diseases in a primary care population: a registry study. <i>BMC Family Practice</i> , 2014, 15, 9.	2.9	9
662	Circulating apelin levels are associated with cardiometabolic risk factors in women with previous gestational diabetes. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 787-793.	0.8	24

#	ARTICLE	IF	CITATIONS
663	Safe Prescription Recommendations for Non Steroidal Anti-inflammatory Drugs: Consensus Document Elaborated by Nominated Experts of Three Scientific Associations (SER-SEC-AEG). Reumatolog&Aa CIÁnica (English Edition), 2014, 10, 68-84.	0.2	9
664	Update in Cardiology: Vascular Risk and Cardiac Rehabilitation. Revista Espanola De Cardiologia (English Ed), 2014, 67, 203-210.	0.4	12
665	Statins in heart failure“With preserved and reduced ejection fraction. An update. , 2014, 141, 79-91.		30
666	Target-Attainment Rates of Low-Density Lipoprotein Cholesterol Using Lipid-Lowering Drugs One Year After Acute Myocardial Infarction in Sweden. American Journal of Cardiology, 2014, 113, 17-22.	0.7	10
667	Effect of change in systolic blood pressure between clinic visits on estimated 10-year cardiovascular disease risk. Journal of the American Society of Hypertension, 2014, 8, 159-165.	2.3	7
668	Effects of exercise training on systo“diastolic ventricular dysfunction in patients with hypertension: an echocardiographic study with tissue velocity and strain imaging evaluation. Hypertension Research, 2014, 37, 649-654.	1.5	27
669	Atherogenic dyslipidemia: prevalence and management in lipid clinics. Revista Ciínica Espanõla, 2014, 214, 491-498.	0.3	6
670	Work Productivity Loss and Indirect Costs Associated with New Cardiovascular Events in High-Risk Patients with Hyperlipidemia - Estimates from Population-Based Register Data in Sweden. Value in Health, 2014, 17, A327-A328.	0.1	0
671	Cardiovascular risk analysis by means of pulse morphology and clustering methodologies. Computer Methods and Programs in Biomedicine, 2014, 117, 257-266.	2.6	7
672	Exercise for people with high cardiovascular risk. The Cochrane Library, 2014, , CD009387.	1.5	12
673	Effects of a comprehensive cardiac rehabilitation program in patients with coronary heart disease in <sc>K</sc>orea. Australian Journal of Cancer Nursing, 2014, 16, 476-482.	0.8	10
675	Ãvaluation du risque cardiovasculaire selon lâindice SCORE national calibrÃ chez les patients atteints de rhumatisme psoriasique sans maladie cardiovasculaire clinique Ãvidente ni de facteurs de risque classiques dâathÃroscleÃrose. Revue Du Rhumatisme (Edition Francaise), 2014, 81, 154-158.	0.0	0
676	Strategies for treating lipids for prevention: Risk stratification models with and without imaging. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 295-307.	2.2	3
677	Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial. European Heart Journal, 2014, 35, 1411-1420.	1.0	46
678	Discordance between high non-HDL cholesterol and high LDL-cholesterol among US adults. Journal of Clinical Lipidology, 2014, 8, 86-93.	0.6	36
679	Myopathies aux statines. NPC Neurologie - Psychiatrie - Geriatrie, 2014, 14, 11-16.	0.1	0
681	Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study. Archives of Cardiovascular Diseases, 2014, 107, 112-121.	0.7	40
682	Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: Can we do better? Analysis of results obtained during the past two decades in 1669 French subjects. Atherosclerosis, 2014, 234, 136-141.	0.4	51

#	ARTICLE	IF	CITATIONS
683	Tragopogon porrifolius improves serum lipid profile and increases short-term satiety in rats. <i>Appetite</i> , 2014, 72, 1-7.	1.8	10
684	Cardiovascular risk assessment according to a national calibrated score risk index in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. <i>Joint Bone Spine</i> , 2014, 81, 164-168.	0.8	11
685	State of secondary prevention in Czech coronary patients in the EUROASPIRE IV study. <i>Cor Et Vasa</i> , 2014, 56, e105-e112.	0.1	3
688	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.2	83
689	Adherence to lifestyle modifications after a cardiac rehabilitation program and endothelial progenitor cells. <i>Thrombosis and Haemostasis</i> , 2014, 112, 196-204.	1.8	7
690	Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review. <i>Food and Nutrition Research</i> , 2014, 58, 25145.	1.2	278
691	Implementation of Telephone-Based Secondary Preventive Intervention after Stroke and Transient Ischemic Attack - Participation Rate, Reasons for Nonparticipation and One-Year Mortality. <i>Cerebrovascular Diseases Extra</i> , 2014, 4, 28-39.	0.5	8
692	Pharmacological lipid lowering for prevention of cardiovascular disease in older adults. <i>Clinical Practice (London, England)</i> , 2014, 11, 49-58.	0.1	2
694	Improvement in the estimation of cardiovascular risk by carotid intima-medial thickness: A report from the Dublin Cardiohealth station study. <i>Preventive Medicine Reports</i> , 2015, 2, 725-729.	0.8	11
695	The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA / Plejotropni Efekti Atorvastatina Kod Pacijenata Sa Stabilnom Anginom: Dokazi Dobijeni Analizom VeliĀine Ā Raspodele Subfrakcija Lipoproteina VeliĀe Gustine Ā Plazmatske mRNA. <i>Journal of Medical Biochemistry</i> , 2015, 34, 314-322.	0.7	1
696	Measurement of ECG abnormalities and cardiovascular risk classification: a cohort study of primary care patients in the Netherlands. <i>British Journal of General Practice</i> , 2015, 65, e1-e8.	0.7	15
697	Patients' Experiences of NurseĀled Screening for Cardiovascular Risk in Rheumatoid Arthritis. <i>Musculoskeletal Care</i> , 2015, 13, 236-247.	0.6	15
698	Association between concomitant psychiatric drug use, and patients' beliefs about and persistence with chronic cardiovascular medication. <i>International Journal of Clinical Practice</i> , 2015, 69, 328-335.	0.8	2
699	Separate and co-administration of <i>Amaranthus spinosus</i> and vitamin C modulates cardiovascular disease risk in high fat diet-fed experimental rats. <i>Journal of Pharmacognosy and Phytotherapy</i> , 2015, 7, 27-34.	0.2	2
700	Treinamento aerĀbio intenso promove reduĀo da pressĀo arterial em hipertensos. <i>Revista Brasileira De Medicina Do Esporte</i> , 2015, 21, 292-296.	0.1	2
701	Impact of predictors upon the reduction of lipid parameters in family medicine practice. <i>Sao Paulo Medical Journal</i> , 2015, 133, 428-434.	0.4	0
702	Arterial stiffness and increased cardiovascular risk in chronic kidney disease. <i>International Urology and Nephrology</i> , 2015, 47, 1157-1164.	0.6	21
703	Copeptin and arginine vasopressin at high altitude: relationship to plasma osmolality and perceived exertion. <i>European Journal of Applied Physiology</i> , 2015, 115, 91-98.	1.2	12

#	ARTICLE	IF	CITATIONS
704	Efecto a largo plazo de los estanoles vegetales en el perfil lipídico de pacientes con hipercolesterolemia. Ensayo clínico aleatorizado. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 665-671.	0.6	15
705	NSAID“antihypertensive drug interactions: Which outpatients are at risk for a rise in systolic blood pressure?. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 91-99.	0.8	11
706	Construction and validation of a model to predict nonadherence to guidelines for prescribing antiplatelet therapy to hypertensive patients. <i>Current Medical Research and Opinion</i> , 2015, 31, 883-889.	0.9	8
707	Global burden of CVD: focus on secondary prevention of cardiovascular disease. <i>International Journal of Cardiology</i> , 2015, 201, S1-S7.	0.8	219
708	The 10-year anniversary of the European Association for Cardiovascular Prevention and Rehabilitation: achievements and challenges. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1340-1345.	0.8	3
709	Change in calculated cardiovascular risk due to guideline revision: A cross-sectional study in the Netherlands. <i>European Journal of General Practice</i> , 2015, 21, 217-223.	0.9	6
710	The use of medications in the secondary prevention of coronary artery disease in the Asian region. <i>Current Medical Research and Opinion</i> , 2015, 31, 423-433.	0.9	3
711	Prediction of atrial fibrillation recurrence after cardioversion in patients with left-atrial dilation. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 335-341.	0.5	44
712	Cardiovascular risk assessment in rheumatoid arthritis: What goals should be achieved?. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, e20-e21.	1.6	0
713	Suitability of antiplatelet therapy in hypertensive patients. <i>Journal of Human Hypertension</i> , 2015, 29, 40-45.	1.0	5
714	Visualization of Coronary Artery Calcification: Influence on Risk Modification. <i>American Journal of Medicine</i> , 2015, 128, 1023.e23-1023.e31.	0.6	15
715	Team-based Care for Cardiac Rehabilitation and Exercise Training in Heart Failure. <i>Heart Failure Clinics</i> , 2015, 11, 431-449.	1.0	5
716	Use of implantable cardioverter-defibrillators in athletes: A systematic review. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2015, 34, 411-419.	0.2	2
717	Prevention of cardiovascular disease in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2015, 14, 952-969.	2.5	69
718	Athletes with Implantable Cardioverter Defibrillators. <i>Clinics in Sports Medicine</i> , 2015, 34, 473-487.	0.9	11
719	Possible mechanisms of C-reactive protein mediated acute myocardial infarction. <i>European Journal of Pharmacology</i> , 2015, 760, 72-80.	1.7	40
720	The ERICE-score: the New Native Cardiovascular Score for the Low-risk and Aged Mediterranean Population of Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 205-215.	0.4	12
722	Practice Variation in Long-term Secondary Stroke Prevention in The Netherlands. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 566-572.	0.7	5

#	ARTICLE	IF	CITATIONS
723	Cardiovascular disease (CVD) risk factors in older adults – Perception and reality. Archives of Gerontology and Geriatrics, 2015, 61, 88-92.	1.4	29
724	Measurement of change in health status with Rasch models. Health and Quality of Life Outcomes, 2015, 13, 16.	1.0	49
725	Cardiovascular risk stratification in overweight or obese patients in primary prevention. Implications for use of statins. Endocrinología Y Nutrición (English Edition), 2015, 62, 83-90.	0.5	2
726	Workplace Exercise and Educational Program for Improving Fitness Outcomes Related to Health in Workers. Journal of Occupational and Environmental Medicine, 2015, 57, 235-240.	0.9	19
727	Long-term Effects of Plant Stanols on the Lipid Profile of Patients With Hypercholesterolemia. A Randomized Clinical Trial. Revista Espanola De Cardiología (English Ed), 2015, 68, 665-671.	0.4	12
728	Promotion of cardiorespiratory fitness in schizophrenia: a clinical overview and meta-analysis. Acta Psychiatrica Scandinavica, 2015, 132, 131-143.	2.2	108
729	Cochrane corner: exercise for people with high cardiovascular risk. Heart, 2015, 101, 663-664.	1.2	0
731	The burden of behavioral risk factors for cardiovascular disease in Europe. A significant prevention deficit. Preventive Medicine, 2015, 81, 326-332.	1.6	12
732	Implementation of Cardiovascular Disease Prevention Guidelines in Clinical Practice – Can We Do Better?. Current Treatment Options in Cardiovascular Medicine, 2015, 17, 58.	0.4	8
733	The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease. Brain, 2015, 138, 2814-2833.	3.7	380
734	Clinical management of patients with hypertension and high cardiovascular risk in specialised centers and in general practice. Analysis from an Italian Survey Questionnaire. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 866-874.	1.1	4
735	Antilipidemic Drug Therapy Today and in the Future. Handbook of Experimental Pharmacology, 2015, 233, 373-435.	0.9	5
737	Utilização de cardioversores desfibriladores implantáveis em desportistas: revisão sistemática. Revista Portuguesa De Cardiologia, 2015, 34, 411-419.	0.2	2
738	Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. European Heart Journal, 2015, 36, ehv352.	1.0	116
739	Effectiveness of multifactorial interventions in primary health care settings for primary prevention of cardiovascular disease: A systematic review of systematic reviews. Preventive Medicine, 2015, 76, S68-S75.	1.6	34
740	Ischemic cardiovascular involvement in psoriasis: A systematic review. International Journal of Cardiology, 2015, 178, 191-199.	0.8	26
742	Cross sectional study on arterial hypertension in a general practice setting. Italian Journal of Medicine, 2016, 10, 128.	0.2	0
743	Risk factor indicators in offspring of patients with premature coronary heart disease in Banja Luka region/Republic of Srpska/Bosnia and Herzegovina. Archives of Medical Science, 2016, 4, 736-741.	0.4	5

#	ARTICLE	IF	CITATIONS
744	The CAPITAL study (CArdiovascular Prevention wIth Telecardiology in ApuLia). Journal of Cardiovascular Medicine, 2016, 17, 455-461.	0.6	6
745	Analysing the concept of diagnostic inertia in hypertension: a cross-sectional study. International Journal of Clinical Practice, 2016, 70, 619-624.	0.8	7
746	Long-term secondary prevention of acute myocardial infarction (SEPAT) â€“ guidelines adherence and outcome. BMC Cardiovascular Disorders, 2016, 16, 226.	0.7	26
748	LONG-TERM EFFECT OF ADRENALECTOMY ON CARDIOVASCULAR REMODELING IN PATIENTS WITH PHEOCHROMOCYTOMA. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2422.	1.8	14
749	A comparison of secondary prevention practice inÂpoststroke and coronary heart disease patients. Public Health, 2016, 137, 64-72.	1.4	5
750	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2016, 37, 2315-2381.	1.0	5,370
751	Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). Maturitas, 2016, 89, 63-72.	1.0	67
752	Equity impact analysis of medical approaches to cardiovascular diseases prevention in Tanzania. Social Science and Medicine, 2016, 170, 208-217.	1.8	6
753	LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population. Journal of Diabetes and Its Complications, 2016, 30, 1631-1639.	1.2	5
754	Lipidâ€lowering treatment patterns in patients with new cardiovascular events â€“ estimates from populationâ€based register data in Sweden. International Journal of Clinical Practice, 2016, 70, 222-228.	0.8	1
755	Managing the lipid profile of coronary heart disease patients. Expert Review of Cardiovascular Therapy, 2016, 14, 1263-1271.	0.6	8
756	2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis, 2016, 252, 207-274.	0.4	415
757	Fibrates for primary prevention of cardiovascular disease events. The Cochrane Library, 2017, 2017, CD009753.	1.5	78
758	Increased homocysteine plasma level is associated with shortened prothrombin time in HIV-infected patients. HIV Clinical Trials, 2016, 17, 218-223.	2.0	4
759	Primary prevention and risk factor reduction in coronary heart disease mortality among working aged men and women in eastern Finland over 40 years: population based observational study. BMJ, The, 2016, 352, i721.	3.0	93
760	Associations of proteins relevant to MAPK signaling pathway (p38MAPK-1,HIF-1 and HO-1) with coronary lesion characteristics and prognosis of peri-menopausal women. Lipids in Health and Disease, 2016, 15, 187.	1.2	8
761	Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population. BMC Family Practice, 2016, 17, 110.	2.9	12
762	Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden. European Journal of Health Economics, 2016, 17, 1117-1124.	1.4	22

#	ARTICLE	IF	CITATIONS
763	Role of heat shock proteins in the cardioprotection of regular moderate alcohol consumption. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 292-300.	0.1	4
764	Smoking Cessation After Acute Myocardial Infarction in Relation to Depression and Personality Factors. <i>International Journal of Behavioral Medicine</i> , 2016, 23, 234-242.	0.8	6
765	PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions. <i>Hellenic Journal of Cardiology</i> , 2016, 57, 86-91.	0.4	19
766	Cardiovascular risk estimation in older persons: SCORE O.P.. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1093-1103.	0.8	138
767	Arterial stiffness in periodontitis patients and controls. <i>Journal of Human Hypertension</i> , 2016, 30, 24-29.	1.0	33
768	Effects of a beverage rich in (poly)phenols on established and novel risk markers for vascular disease in medically uncomplicated overweight or obese subjects: A four week randomized placebo-controlled trial. <i>Atherosclerosis</i> , 2016, 246, 169-176.	0.4	17
770	Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis. <i>American Journal of Hypertension</i> , 2016, 29, 509-518.	1.0	23
772	The use of HeartQoL in patients with coronary heart disease: Association with risk factors and European reference values. The EUROASPIRE IV study of the European Society of Cardiology. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1174-1186.	0.8	14
773	Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial. <i>Gynecological Endocrinology</i> , 2016, 32, 477-482.	0.7	21
774	Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 349-357.	0.8	11
775	Incidence of acute mountain sickness in UK Military Personnel on Mount Kenya. <i>Journal of the Royal Army Medical Corps</i> , 2016, 162, 465-469.	0.8	4
776	Drug-symptom networking: Linking drug-likeness screening to drug discovery. <i>Pharmacological Research</i> , 2016, 103, 105-113.	3.1	8
777	Dialysis in terms of reducing cardiovascular events. <i>International Journal of Cardiology</i> , 2016, 202, 97.	0.8	0
778	Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data. <i>European Journal of Health Economics</i> , 2016, 17, 591-601.	1.4	22
779	Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: Data from the SWEDHEART registry. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 340-348.	0.8	58
780	Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival. <i>Rheumatology International</i> , 2017, 37, 75-84.	1.5	58
781	Efficacy of omega-3 polyunsaturated fatty acids supplementation in managing overweight and obesity: A meta-analysis of randomized clinical trials. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 187-192.	1.5	65
782	Genetic analysis in post-mortem samples with micro-ischemic alterations. <i>Forensic Science International</i> , 2017, 271, 120-125.	1.3	1

#	ARTICLE	IF	CITATIONS
783	Cholesterol-lowering drugs: science and marketing. <i>Journal of the Royal Society of Medicine</i> , 2017, 110, 57-64.	1.1	7
784	Physical activity prescription by primary care nurses using health assets: Study design of a randomized controlled trial in patients with cardiovascular risk factors. <i>Journal of Advanced Nursing</i> , 2017, 73, 2191-2200.	1.5	5
785	Is there a role for lifestyle changes in cardiovascular prevention? What, when and how?. <i>Atherosclerosis Supplements</i> , 2017, 26, 2-15.	1.2	31
786	Niacin for primary and secondary prevention of cardiovascular events. <i>The Cochrane Library</i> , 2017, 2017, CD009744.	1.5	43
787	Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study. <i>Journal of the Saudi Heart Association</i> , 2017, 29, 235-243.	0.2	82
788	Association Between Improvement in Cardiovascular Risk Profile and Changes in Sickness Absence: Results of the ICARIA Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 941-951.	0.4	1
789	Awareness and knowledge of cardiovascular disease risk factors among medical students. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 458-463.	1.0	12
790	Cardiorespiratory fitness, but not physical activity, is associated with academic achievement in children and adolescents. <i>Annals of Human Biology</i> , 2017, 44, 309-315.	0.4	14
791	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>International Journal of Behavioral Medicine</i> , 2017, 24, 321-419.	0.8	84
792	Nurse-coordinated care improves the achievement of LDL cholesterol targets through more intensive medication titration. <i>Open Heart</i> , 2017, 4, e000607.	0.9	4
793	A real life registry to evaluate patient profile, diagnostic and practice patterns in Acute Coronary Syndrome in Turkey: TURK-AKS study. <i>International Journal of the Cardiovascular Academy</i> , 2017, 3, 85-93.	0.1	3
795	The relation between gallstone disease and cardiovascular disease. <i>Scientific Reports</i> , 2017, 7, 15104.	1.6	32
796	Effects of a Pedometer-Based Telephone Coaching Intervention on Physical Activity Among People with Cardiac Disease in Urban, Rural and Semi-Rural Settings: A Replication Study. <i>Heart Lung and Circulation</i> , 2017, 26, 354-361.	0.2	6
797	Baseline characteristics of patients with heart failure and preserved ejection fraction at admission with acute heart failure in Saudi Arabia. <i>Egyptian Heart Journal</i> , 2017, 69, 21-28.	0.4	7
798	The Influence of Fiber on Gut Microbiota: Butyrate as Molecular Player Involved in the Beneficial Interplay Between Dietary Fiber and Cardiovascular Health. , 2017, , 61-71.		4
799	The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 633-639.	0.7	47
800	Relative peak exercise oxygen pulse is related to sudden cardiac death, cardiovascular and all-cause mortality in middle-aged men. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 772-782.	0.8	39
801	Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy. <i>Clinical Cardiology</i> , 2018, 41, 788-796.	0.7	9

#	ARTICLE	IF	CITATIONS
802	Reprint of: Proteomics in cardiovascular diseases: Unveiling sex and gender differences in the era of precision medicine. <i>Journal of Proteomics</i> , 2018, 178, 57-72.	1.2	9
803	Long-term Risk of Myocardial Infarction Compared to Recurrent Stroke After Transient Ischemic Attack and Ischemic Stroke: Systematic Review and Meta-analysis. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	101
805	Iodixanol versus Iopromide at Coronary CT Angiography: Lumen Opacification and Effect on Heart Rhythm—the Randomized IsoCOR Trial. <i>Radiology</i> , 2018, 286, 71-80.	3.6	19
806	Exercise training in patients with pulmonary and systemic hypertension: A unique therapy for two different diseases. <i>European Journal of Internal Medicine</i> , 2018, 47, 17-24.	1.0	18
807	Main messages for primary care from the 2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of General Practice</i> , 2018, 24, 51-56.	0.9	36
808	Proteomics in cardiovascular diseases: Unveiling sex and gender differences in the era of precision medicine. <i>Journal of Proteomics</i> , 2018, 173, 62-76.	1.2	21
809	Predictors of adherence to treatment by patients with coronary heart disease after percutaneous coronary intervention. <i>Journal of Clinical Nursing</i> , 2018, 27, 989-1003.	1.4	32
810	Hypotensive Effect of Heated Water-Based Exercise Persists After 12-Week Cessation of Training in Patients With Resistant Hypertension. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1641-1647.	0.8	15
811	Compliance With Dyslipidemia Guidelines in Daily Practice: How Effective Is Cardiovascular Risk Prevention?. <i>Clinical Therapeutics</i> , 2018, 40, 2031-2040.	1.1	0
812	Potential gains in life expectancy by eliminating deaths from cardiovascular diseases and diabetes mellitus in the working life ages among Slovak population. <i>Health Economics Review</i> , 2018, 8, 16.	0.8	7
813	Decomposition of gendered income-related inequalities in multiple biological cardiovascular risk factors in a middle-aged population. <i>International Journal for Equity in Health</i> , 2018, 17, 102.	1.5	5
814	Cardiovascular risk factors in adult general out-patient clinics in Nigeria: a country analysis of the Africa and Middle East Cardiovascular Epidemiological (ACE) study.. <i>African Health Sciences</i> , 2018, 17, 1070.	0.3	11
815	Microfibrillar-associated protein 4 variation in symptomatic peripheral artery disease. <i>Journal of Translational Medicine</i> , 2018, 16, 159.	1.8	18
816	Scientific and technical assistance on trans fatty acids. <i>EFSA Supporting Publications</i> , 2018, 15, 1433E.	0.3	17
817	Metabolic syndrome and its components in Polish women of childbearing age: a nationwide study. <i>BMC Public Health</i> , 2018, 18, 15.	1.2	17
818	Current and future applications of CT coronary calcium assessment. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 441-453.	0.6	11
819	Relationship between serum lipid concentrations and posttraumatic stress symptoms in the bereaved after the Sewol ferry disaster: A prospective cohort study. <i>Psychiatry Research</i> , 2018, 266, 132-137.	1.7	8
820	Lipoprotein(a) concentration is associated with plasma arachidonic acid in subjects with familial hypercholesterolaemia. <i>British Journal of Nutrition</i> , 2019, 122, 790-799.	1.2	4

#	ARTICLE	IF	CITATIONS
821	Attainment of cholesterol target values in Greece: results from the Dyslipidemia International Study II. Archives of Medical Science, 2019, 15, 821-831.	0.4	8
822	Improved unhealthy lifestyle habits in patients with high cardiovascular risk: results from a structured lifestyle programme in primary care. Upsala Journal of Medical Sciences, 2019, 124, 94-104.	0.4	11
823	Impact of chronic kidney disease on recurrent ventricular tachyarrhythmias in ICD recipients. Heart and Vessels, 2019, 34, 1811-1822.	0.5	6
824	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis, 2019, 285, 135-146.	0.4	227
825	Cardiorespiratory Fitness and the Risk of First Acute Myocardial Infarction: The HUNT Study. Journal of the American Heart Association, 2019, 8, e010293.	1.6	20
826	Deep learning in ophthalmology: The technical and clinical considerations. Progress in Retinal and Eye Research, 2019, 72, 100759.	7.3	300
827	Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovascular Disorders, 2019, 19, 61.	0.7	6
828	Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. Arthritis and Rheumatology, 2019, 71, 1225-1231.	2.9	11
829	Age, Sex, and Cardiovascular Risk Attributable to Lipoprotein Cholesterol Among Chinese Individuals with Coronary Artery Disease: A Caseâ€“Control Study. Metabolic Syndrome and Related Disorders, 2019, 17, 223-231.	0.5	9
830	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology, 2019, 26, 824-835.	0.8	558
831	Inadequate control of atherosclerotic cardiovascular disease risk factors in Europe: EUROASPIRE repeats itself. European Journal of Preventive Cardiology, 2019, 26, 820-823.	0.8	8
832	To what extent can the chosen blood pressure measurement technique affect the outcomes of an observational survey?. Journal of Comparative Effectiveness Research, 2019, 8, 841-852.	0.6	0
833	Motivators and Deterrents to Diet Change in Low Socio-Economic Pakistani Patients With Cardiovascular Disease. Global Qualitative Nursing Research, 2019, 6, 233339361988360.	0.7	5
835	Endothelial Dysfunction in Early Phases of Hypertension. Updates in Hypertension and Cardiovascular Protection, 2019, , 291-306.	0.1	0
836	Lifestyle behaviour and risk factor control in coronary patients: Belgian results from the cross-sectional EUROASPIRE surveys. Acta Cardiologica, 2019, 74, 21-27.	0.3	3
837	40-Year CHD Mortality Trends and the Role of Risk Factors in Mortality Decline: The North Karelia Project Experience. Global Heart, 2016, 11, 207.	0.9	44
838	Cardiovascular risk assessment models: Have we found the perfect solution yet?. Journal of Nuclear Cardiology, 2020, 27, 2375-2385.	1.4	6
839	Effects of exercise training in heart failure with preserved ejection fraction: an updated systematic literature review. Heart Failure Reviews, 2020, 25, 703-711.	1.7	42

#	ARTICLE	IF	CITATIONS
840	Chronic medication intake in patients with stable coronary heart disease across Europe: Evidence from the daily clinical practice. Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) Registry. <i>International Journal of Cardiology</i> , 2020, 300, 7-13.	0.8	9
841	The presence of fragmented QRS may predict the recurrence of nonvalvular atrial fibrillation after successful electrical cardioversion. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12700.	0.5	4
842	The thromboelastography G parameter as a potential biomarker of acute coronary syndrome. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2020, 80, 196-201.	0.6	2
843	Cardiovascular disease risk perception in a Hungarian community sample: psychometric evaluation of the ABCD Risk Perception Questionnaire. <i>BMJ Open</i> , 2020, 10, e036028.	0.8	8
844	Instruments to assess self-efficacy among people with cardiovascular disease: A COSMIN systematic review. <i>International Journal of Clinical Practice</i> , 2020, 74, e13606.	0.8	2
845	Psychosocial Cardiological Schedule-Revised (PCS-R) in a Cardiac Rehabilitation Unit: Reflections Upon Data Collection (2010-2017) and New Challenges. <i>Frontiers in Psychology</i> , 2020, 11, 1720.	1.1	2
846	Cardiovascular risk in persons at risk of developing rheumatoid arthritis. <i>PLoS ONE</i> , 2020, 15, e0237072.	1.1	10
847	Association between glutathione peroxidase activity and carotid atherosclerosis in patients with type 2 diabetes mellitus. <i>Brain and Behavior</i> , 2020, 10, e01773.	1.0	13
848	Care management of patients with high cardiovascular risk in Hungary an international and Hungarian longitudinal comparison of target level achievement. <i>BMC Family Practice</i> , 2020, 21, 83.	2.9	3
849	30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985 - 2016/17. <i>PLoS ONE</i> , 2020, 15, e0232845.	1.1	34
850	External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti-inflammatory Drug Users: Real-World Application. <i>ACR Open Rheumatology</i> , 2020, 2, 269-275.	0.9	0
851	The responses of different dosages of egg consumption on blood lipid profile: An updated systematic review and meta-analysis of randomized clinical trials. <i>Journal of Food Biochemistry</i> , 2020, 44, e13263.	1.2	13
852	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 370-379.	0.8	83
853	Is there an association between sarcoidosis and atherosclerosis?. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 559-567.	0.7	4
854	Effectiveness of physical activity prescription by primary care nurses using health assets: A randomized controlled trial. <i>Journal of Advanced Nursing</i> , 2021, 77, 1518-1532.	1.5	6
855	Thrombolysis In Myocardial Infarction (TIMI) Study Group. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2822-2845.	1.2	23
856	Health system gaps in cardiovascular disease prevention and management in Nepal. <i>BMC Health Services Research</i> , 2021, 21, 655.	0.9	5
858	Psychosocial Factors at Work: The Epidemiological Perspective. , 2011, , 195-209.		1

#	ARTICLE	IF	CITATIONS
859	Individual Interventions for Prevention and Control of CVDs. , 2015, , 237-244.		1
860	Psychische Störungen bei somatischen Krankheiten. , 2015, , 1-114.		2
861	Diagnosis and Treatment of Non-“ST-Segment Elevation Acute Coronary Syndromes. , 2011, , 369-384.		2
863	Will screening individuals at high risk of cardiovascular events deliver large benefits? No. <i>BMJ: British Medical Journal</i> , 2008, 337, a1395-a1395.	2.4	36
864	Diagnostic accuracy of heart fatty acid binding protein (H-FABP) and glycogen phosphorylase isoenzyme BB (GPBB) in diagnosis of acute myocardial infarction in patients with acute coronary syndrome. <i>Biochemia Medica</i> , 2012, 22, 225-236.	1.2	25
865	Are Markers of Inflammation More Strongly Associated with Risk for Fatal Than for Nonfatal Vascular Events?. <i>PLoS Medicine</i> , 2009, 6, e1000099.	3.9	87
866	The Effect of Telephone Support Interventions on Coronary Artery Disease (CAD) Patient Outcomes during Cardiac Rehabilitation: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e96581.	1.1	43
867	Accumulation of Cardiovascular and Diabetes Medication among Apparently Healthy Statin Initiators. <i>PLoS ONE</i> , 2015, 10, e0117182.	1.1	1
868	Intima-media complex thickness and carotid atherosclerotic plaque formation in Lublin’s population in the context of selected comorbidities. <i>Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ-SzopiÅska</i> , 2018, 18, 133-139.	0.7	7
869	Is there a possible relationship between gastric intestinal metaplasia and systemic arterial stiffness?. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 500-506.	0.1	7
870	Cardiovascular Risk Factor Burden in the United Arab Emirates (UAE): The Africa Middle East (AfME) Cardiovascular Epidemiological (ACE) Study Sub-analysis. <i>International Cardiovascular Forum Journal</i> , 0, 11, .	1.1	7
871	Selected cardiovascular risk markers in vegetarians and subjects of general population. <i>Central European Journal of Public Health</i> , 2017, 25, 299-302.	0.4	2
872	Global Cardiovascular Risk Management in Primary Prevention. <i>Current Vascular Pharmacology</i> , 2012, 10, 709-711.	0.8	3
873	Dyslipidemia and Cardiovascular Disease Risk Factor Management in HIV-1-Infected Subjects Treated with HAART in the Spanish VACH Cohort. <i>Open AIDS Journal</i> , 2008, 2, 26-38.	0.1	26
874	Effects Of Internet-Based Tailored Advice on the Use of Cholesterol-Lowering Interventions: A Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2010, 12, e42.	2.1	12
875	Remotely Delivered Exercise-Based Cardiac Rehabilitation: Design and Content Development of a Novel mHealth Platform. <i>JMIR MHealth and UHealth</i> , 2016, 4, e57.	1.8	41
876	Measurement and Data Transmission Validity of a Multi-Biosensor System for Real-Time Remote Exercise Monitoring Among Cardiac Patients. <i>JMIR Rehabilitation and Assistive Technologies</i> , 2015, 2, e2.	1.1	20
877	Correlation between mean platelet volume and total risk of cardiovascular disease. <i>Signa Vitae</i> , 2013, 8, 49.	0.8	2

#	ARTICLE	IF	CITATIONS
878	The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 66-70.	0.6	1
879	Position paper on the importance of psychosocial factors in cardiology: Update 2013. <i>GMS German Medical Science</i> , 2014, 12, Doc09.	2.7	62
880	Trends in Cardiovascular Risk Factors Among Patients With Coronary Heart Disease. <i>Deutsches A&#x0308;rztblatt International</i> , 2012, 109, 303-10.	0.6	20
881	Cut-off values of waist circumference to predict metabolic syndrome in obese adolescents. <i>Nutricion Hospitalaria</i> , 2015, 31, 1540-50.	0.2	16
882	Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. <i>Health Technology Assessment</i> , 2013, 17, 1-253.	1.3	75
883	Physical And Behavioural Health Of Older Irish Adults. , 2011, , 73-154.		6
884	Cardiac rehabilitation past, present and future: an overview. <i>Cardiovascular Diagnosis and Therapy</i> , 2012, 2, 38-49.	0.7	180
885	Association between Metabolic Components and Subclinical Atherosclerosis in Korean Adults. <i>Korean Journal of Family Medicine</i> , 2012, 33, 229.	0.4	11
886	Physical activity level improves the predictive accuracy of cardiovascular disease risk score: The ATTICA study (2002-2012). <i>International Journal of Preventive Medicine</i> , 2016, 7, 52.	0.2	7
887	Obesity indices in relation to lipid abnormalities among medical university students in Zahedan, South-East of Iran. <i>International Journal of Preventive Medicine</i> , 2019, 10, 15.	0.2	6
888	Lifestyle changes in coronary heart diseaseâ€™Effects of cardiac rehabilitation programs with focus on intensity, duration and contentâ€™A systematic review. <i>Open Journal of Nursing</i> , 2012, 02, 420-430.	0.2	4
889	Letter to the Editor Atorvastatin in combination with ezetimibe and carotid atherosclerosis. <i>Genetics and Molecular Research</i> , 2014, 13, 4805-4807.	0.3	5
890	Study of Patient Information after percutaneous Coronary Intervention (SPICI): should prevention programmes become more effective?. <i>EuroIntervention</i> , 2015, 10, e1-e7.	1.4	36
891	â€™Rehabilitationâ€™after PCI: nonsense or the only way to achieve lasting results?. <i>EuroIntervention</i> , 2010, 5, 655-658.	1.4	3
892	Cardiovascular risk profile of patients included in stent trials; a pooled analysis of individual patient data from randomised clinical trials: insights from 33 prospective stent trials in Europe. <i>EuroIntervention</i> , 2011, 7, 859-871.	1.4	4
893	Health Benefits of Exercise. <i>FTR - Turkiye Fiziksel Tip Ve Rehabilitasyon Dergisi</i> , 2014, 60, 9-14.	0.1	12
894	Metabolic syndrome, inflammation and atherothrombosis. <i>Hamostaseologie</i> , 2013, 33, 283-294.	0.9	13
895	Adherence to Preferable Behavior for Lipid Control by High-Risk Dyslipidemic Japanese Patients Under Pravastatin Treatment: the APPROACH-J Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 795-805.	0.9	9

#	ARTICLE	IF	CITATIONS
896	The effect of cycle ergometer exercise training on improvement of exercise capacity in patients after myocardial infarction. <i>Kardiologia Polska</i> , 2013, 71, 1059-1064.	0.3	8
897	Clinical characteristics, aetiology and occurrence of type 2 acute myocardial infarction. <i>Kardiologia Polska</i> , 2014, 72, 339-344.	0.3	45
898	Relationship between 28-year food consumption trends and the 10-year global risk of death due to cardiovascular diseases in the adult Warsaw population. <i>Kardiologia Polska</i> , 2015, 73, 650-655.	0.3	3
899	Klasifikacija, epidemiologija, faktori rizika i primarna prevencija ishemijske bolesti srca. <i>Srce I Krvni Sudovi</i> , 2011, 30, 145-149.	0.1	2
900	IntervenĂo coronariana percutĂnea em pacientes com mais de 70 anos: anĂlise de desfechos intra-hospitalares na era contemporĂnea. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2008, 16, 64-69.	0.1	1
901	Stimulerende middelen: tabak. , 2008, , 164-195.		0
902	To What Extent are National Cardiovascular Disease Preventive Guidelines Accomplished in Hungary? The Goal Attainment Program (GAP). <i>Hungarian Medical Journal</i> , 2008, 2, 593-602.	0.0	1
904	The Metabolic Syndrome. , 2009, , 423-445.		0
905	Nutrition Recommendations and Interventions for Subjects with Cardiovascular Disease. , 2009, , 221-244.		0
907	AterotrombĂza: antiagregaĂba. <i>Cor Et Vasa</i> , 2009, 51, 19-21.	0.1	1
908	Mechanisms of Redox Signaling in Cardiovascular Disease. , 2010, , 43-60.		0
909	Diabetes Mellitus Type 2 and Cardiovascular Disease. , 2010, , 137-150.		0
910	Implementation of secondary prevention methodologies in ischemic heart disease. <i>Scripta Medica</i> , 2010, 41, 29-35.	0.0	2
911	History of the Evolution of Cardiovascular Risk Factors and the Predictive Value of Traditional Risk-Factor-Based Risk Assessment. , 2011, , 89-105.		0
912	Cardiovascular risk management in patients with inflammatory arthritis: what is good for the joint is good for the heart and vice versa!. <i>F1000 Medicine Reports</i> , 2010, 2, .	2.9	0
913	Cardiac CT in Clinical Practice. , 2011, , 33-41.		0
914	Stabilna angina pektoris. <i>Srce I Krvni Sudovi</i> , 2011, 30, 156-160.	0.1	0
915	Postcoronary diet therapy. , 2011, , 667-670.		0

#	ARTICLE	IF	CITATIONS
916	Kardialer Check-up. , 2011, , 263-298.		0
918	Regulation of risk factors in patients with ischemic heart disease treated with percutaneous coronary intervention. Srce I Krvni Sudovi, 2011, 30, 257-263.	0.1	1
919	Lipid management after a coronary event. , 2011, , 328-337.		0
920	ACE-inhibitors and angiotensin receptor blockers. , 2011, , 247-252.		0
921	Cardiovascular risk and lipid control in secondary prevention. Srce I Krvni Sudovi, 2011, 30, 210-219.	0.1	0
922	PSIHOLOÅKE REAKCIJE I ZDRAVSTVENO PONAÅANJE NAKON AKUTNOG INFARKTA MIOKARDA. Acta Medica Medianae, 2011, , 18-23.	0.0	0
923	Ultrasound Strain and Strain Rate Imaging of the Early Sage of Carotid Artery with Type 2 Diabetes Mellitus. Lecture Notes in Electrical Engineering, 2012, , 1079-1087.	0.3	0
924	Ankle-Brachial Index as a Predictor of Cardiovascular Risk in Atrial Fibrillation. Journal of Clinical & Experimental Cardiology, 2012, 03, .	0.0	0
925	Lipoprotein Disorders and Cardiovascular Disease. , 2012, , 975-995.		5
926	Statins: have we found the Holy Grail?. Swiss Medical Weekly, 2012, 142, w13515.	0.8	12
927	Ethnic Difference in Lipid Profiles. , 0, , .		2
928	Optimization of primary and secondary prevention. , 2012, , 259-277.		0
931	Taking measures of secondary prevention of coronary heart disease in clinical practice. Srce I Krvni Sudovi, 2013, 32, 205-207.	0.1	1
933	PROMENE PSIHOLOÅKIH PARAMETARA I ZDRAVSTVENOG PONAÅANJA KORONARNIH I NEKORONARNIH BOLESNIKA NAKON HOSPITALIZACIJE-ÅESTOMESEÅCENO PRAÅ†ENJE. Acta Medica Medianae, 2013, , 12-19.	0.0	0
935	Current cholesterol guidelines and clinical reality: a comparison of two cohorts of coronary artery disease patients. Swiss Medical Weekly, 2013, 143, w13828.	0.8	9
936	Editorial: Sailing across the sea of guidelines. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2013, 20, 361-367.	0.3	0
937	Has the Antiplatelet Therapy a Role in the Prevention of Sudden Cardiac Death?. Cardiovascular Pharmacology: Open Access, 2014, 04, .	0.1	0
938	Moving Medical Semeiotics to the Digital Realm - SEMEOTICONS Approach to Face Signs of Cardiometabolic Risk. , 2014, , .		1

#	ARTICLE	IF	CITATIONS
939	Lipids and hyperlipidaemia. , 2014, , 823-846.		0
941	Endothelial Function in Obese and Overweight Patients: The Role of Olive Oil, Fish and Nuts. International Journal of Diabetes and Clinical Research, 2014, 1, .	0.1	2
942	Multifactorial Analysis of Cardiovascular Risk Factors in a Group of Patients with Acute Myocardial Infarction. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2014, 21, 327-333.	0.3	0
943	Effectiveness of a Short Duration Training Programme in the Physical Fitness of Patients with High-Moderate Risk of Cardiovascular Disease. Open Journal of Preventive Medicine, 2015, 05, 218-226.	0.2	2
944	Znajomość czynników ryzyka choroby wieńcowej w rodzinie mieszkańców województwa lubelskiego i województwa łódzkiego. Folia Cardiologica, 2015, 10, 9-15.	0.1	0
946	Acetylsalicylic acid use in primary prevention in Canada: Insight from the Primary Care Audit of Global Risk Management (PARADIGM) study. Current Research Cardiology, 2016, 3, .	0.1	0
947	Interdisciplinary Approach to Cardiovascular Diseases for Research and Everyday Clinical Practice Purposes. Advances in Medical Education, Research, and Ethics, 2016, , 339-371.	0.1	0
948	Artériopathie du patient avec une insuffisance rénale. , 2016, , 465-469.		0
949	Health, not weight loss, focused programmes versus conventional weight loss programmes for cardiovascular risk factors. The Cochrane Library, 0, , .	1.5	0
950	Cardiovascular Disease Risk in Women: What Makes It Different from Men. , 2017, , 1-31.		1
951	New techniques and models for assessing ischemic heart disease risks. Health Risk Analysis, 2017, , 40-47.	0.1	0
952	Hyperuricemia and global Cardiovascular Risk: State of the art and preventive prospects. Archives of Preventive Medicine, 2017, 2, 022-027.	0.0	0
953	Traitement des dyslipidémies. , 2018, , 123-139.e1.		0
954	Interdisciplinary Approach to Cardiovascular Diseases for Research and Everyday Clinical Practice Purposes. , 2019, , 139-171.		1
955	Lipid Control in Patients with Diabetes across Primary and Tertiary Government Health Sectors in Dubai: A Five-year Pattern. Oman Medical Journal, 2019, 34, 290-296.	0.3	1
956	Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II. Singapore Medical Journal, 2019, 60, 454-462.	0.3	4
959	Efficacy of omega-3 polyunsaturated fatty acids supplementation in managing overweight and obesity: A meta-analysis of randomized clinical trials. Journal of Nutrition, Health and Aging, 0, , .	1.5	0
960	Effect of physical activity on the life quality of coronary artery bypass graft patients. Journal of Medicine and Life, 2014, 7, 260-3.	0.4	11

#	ARTICLE	IF	CITATIONS
961	Non-HDL Cholesterol and Evaluation of Cardiovascular Disease Risk. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2010, 21, 64-7.	0.7	10
962	Novel Inflammatory Biomarkers as Additional Value to Traditional Risk-factors in Cardiovascular Risk Stratification. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 1092-1104.	0.1	0
963	Association Between Dietary Salt and Plasma Glucose, Insulin and Hemoglobin A1c Levels Among Type 2 Diabetes Patients in Eastern China. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 4811-4818.	1.1	4
970	Role of ankle brachial pressure index (ABI) in screening patients with risk factors for developing peripheral vascular disease. <i>Indian Journal of Vascular and Endovascular Surgery</i> , 2022, 9, 139.	0.0	0
971	Effect of Metabolic Control on Recurrent Major Adverse Cardiovascular Events and Cardiovascular Mortality in Patients with Premature Coronary Artery Disease: Results of the Genetics of Atherosclerotic Disease Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	1.1	3
972	Effects of Long-Term Intervention with Losartan, Aspirin and Atorvastatin on Vascular Remodeling in Juvenile Spontaneously Hypertensive Rats. <i>Molecules</i> , 2023, 28, 1844.	1.7	0